<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38648452</article-id><article-id pub-id-type="pmc">PMC467007</article-id>
<article-id pub-id-type="publisher-id">IJO-72-354</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_3043_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Management of corneal neovascularization: Current and emerging therapeutic approaches</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Duoduo</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Kai En</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Blanche Xiao Hong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Dawn Ka-Ann</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Wendy Meihua</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Chai</surname><given-names>Charmaine</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Manotosh</surname><given-names>Ray</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lim</surname><given-names>Chris Hong Long</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor1" ref-type="corresp"/></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Ophthalmology, National University Hospital, Singapore</aff><aff id="aff2"><label>2</label>Yong Loo Lin School of Medicine, National University of Singapore, Singapore</aff><aff id="aff3"><label>3</label>School of Optometry and Vision Science, University of New South Wales, Sydney, Australia</aff><aff id="aff4"><label>4</label>Singapore Eye Research Institute, Singapore</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Chris Hong Long Lim, 5 Lower Kent Ridge Road, NUH Medical Centre, Level 17, 119074, Singapore. E-mail: <email xlink:href="chrislimmd@gmail.com">chrislimmd@gmail.com</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>4</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S354</fpage><lpage>S371</lpage><history><date date-type="received"><day>17</day><month>11</month><year>2022</year></date><date date-type="rev-recd"><day>16</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>25</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><p>Corneal neovascularization (CoNV) is a sight-threatening condition affecting an estimated 1.4 million people per year, and the incidence is expected to rise. It is a complication of corneal pathological diseases such as infective keratitis, chemical burn, corneal limbal stem cell deficiency, mechanical trauma, and immunological rejection after keratoplasties. CoNV occurs due to a disequilibrium in proangiogenic and antiangiogenic mediators, involving a complex system of molecular interactions. Treatment of CoNV is challenging, and no therapy thus far has been curative. Anti-inflammatory agents such as corticosteroids are the mainstay of treatment due to their accessibility and well-studied safety profile. However, they have limited effectiveness and are unable to regress more mature neovascularization. With the advent of advanced imaging modalities and an expanding understanding of its pathogenesis, contemporary treatments targeting a wide array of molecular mechanisms and surgical options are gaining traction. This review aims to summarize evidence regarding conventional and emerging therapeutic options for CoNV.</p></abstract><kwd-group><kwd>Anti-VEGF</kwd><kwd>cornea</kwd><kwd>corneal neovascularization</kwd><kwd>gene therapy</kwd></kwd-group></article-meta></front><body><p>Corneal neovascularization (CoNV) is a sight-threatening condition that occurs after pathological insults such as microbial keratitis, herpes simplex keratitis, chemical burn, corneal limbal stem cell deficiency (LSCD), mechanical trauma, and immunological rejection following corneal transplantation. It is characterized by disruption of the cornea&#x02019;s normal avascularity from the invasion of abnormal blood vessels in the stroma [<xref rid="IJO.IJO_3043_23-F1" ref-type="fig">Fig. 1</xref>]. These atypical vessels have increased vascular permeability and can cause chronic corneal edema, lipid and protein exudation, and scar formation leading to disarrangement of the regularly arranged lamellar collagen in the cornea. The loss of transparency can lead to visual impairment and blindness in severe cases. With an estimated annual incidence of 1.4 million people, CoNV represents a significant public health concern.[<xref rid="R1" ref-type="bibr">1</xref>]</p><fig position="float" id="IJO.IJO_3043_23-F1"><label>Figure 1</label><caption><p>Clinical manifestations and etiologies of corneal neovascularization. SJS = Steven&#x02013;Johnson syndrome, TEN = toxic epidermal necrolysis</p></caption><graphic xlink:href="IJO-72-354-g001" position="float"/></fig><p>Unfortunately, despite its prevalence, no curative therapy is available for this condition. Various treatments including anti-inflammatory agents, immunomodulatory drugs, fine needle diathermy (FND), and laser photocoagulation have been proposed to mitigate CoNV. However, these treatments often have limited effectiveness and may be associated with adverse effects. More recently, the introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs has provided new therapeutic options. There is also growing interest in combining different treatment modalities in a synergistic manner to enhance the management of CoNV. This review aims to provide an overview of the existing treatment options for CoNV and shed light on emerging therapeutic approaches for this debilitating condition.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><p>A literature search of the PubMed database was performed to include publications from inception to 2023. The key search terms included but were not limited to &#x0201c;corneal neovascularization,&#x0201d; &#x0201c;CoNV,&#x0201d; &#x0201c;anti-VEGF,&#x0201d; &#x0201c;anti-inflammatory,&#x0201d; &#x0201c;immunosuppressant,&#x0201d; &#x0201c;tyrosine kinase inhibitors,&#x0201d; &#x0201c;laser photocoagulation,&#x0201d; &#x0201c;fine needle diathermy,&#x0201d; &#x0201c;photodynamic therapy,&#x0201d; &#x0201c;gene therapy,&#x0201d; as well as other relevant treatment modalities in the titles and abstracts. In addition, an independent search of current literature and a thorough screening of previous reviews were also conducted to maintain a comprehensive search and article inclusion. Both animal and human clinical studies were included in this review.</p><sec id="sec2-1"><title>Pathogenesis</title><p>The human cornea is an optically important structure. Together with the tear film, they contribute to 70% of the eye&#x02019;s total refractive power. It is made up of six distinct layers &#x02013; the epithelium, Bowman&#x02019;s membrane, stroma, Dua&#x02019;s layers, Descemet&#x02019;s membrane, and the endothelium.[<xref rid="R2" ref-type="bibr">2</xref><xref rid="R3" ref-type="bibr">3</xref>] The stroma contains type I and V collagen fibrils interwoven in a regular fashion, forming layers of stacked lamellae to create an optically transparent media for light to pass through. CoNV is postulated to occur via a disruption in corneal angiogenic privilege due to a disequilibrium in proangiogenic and antiangiogenic factors in the cornea.</p><p>Proangiogenic factors involved in the pathogenesis of CoNV include vascular endothelial growth factor (VEGF), platelet-derived growth factor, matrix metalloproteinase (MMP), and inflammatory cytokines such as interleukin-1 (IL-1) and interleukin-6 (IL-6).[<xref rid="R4" ref-type="bibr">4</xref>] An extensively studied angiogenic mediator is VEGF-A, which is a member of a family of proteins including VEGF-A, VEGF-B, VEGF-C, VEGF-D, virally encoded VEGF-E, and placental growth factor.[<xref rid="R5" ref-type="bibr">5</xref>] VEGF-A is secreted by a wide variety of cells including macrophages, T-cells, fibroblasts, retinal pigment epithelial cells, and corneal cells upon inflammation and insult.[<xref rid="R6" ref-type="bibr">6</xref>] VEGF-A plays a dominant role in regulating angiogenesis by interacting with the tyrosine kinase receptors, VEGF-R1 and VEGF-R2.[<xref rid="R7" ref-type="bibr">7</xref>] VEGF-C and VEGF-D are secreted by the macrophages, and they bind to VEGF-R3 to stimulate lymphangiogenesis. MMPs are Zn<sup>2+</sup>-dependent enzymes categorized as either secreted MMPs or membrane-type MMPs. The first transmembrane-containing MMP to be identified was MMP-14. It has been linked to several molecular mechanisms involved in the selective binding and cleaving of VEGF-R1, which induces corneal angiogenesis.[<xref rid="R8" ref-type="bibr">8</xref>] MMP-2 and MMP-9 contribute to the degradation of extracellular matrix components and the upregulation of VEGF and tumor growth factor-&#x003b2;.[<xref rid="R9" ref-type="bibr">9</xref>] IL-1 and IL-6 are proinflammatory cytokines which upregulate the expression of chemokines and growth factors that lead to neovascularization.[<xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">11</xref>]</p><p>Antiangiogenic factors include endostatin and endostatin analogs (neostatin, arrestin, canstatin, and tumstatin), plasminogen inhibitors, serine protease inhibitors (angiostatin and pigment epithelial-derived factor), and soluble VEGF receptors.[<xref rid="R12" ref-type="bibr">12</xref>] Angiostatin binds to surface proteins in the vascular endothelial cells to hinder migration and tubule formation.[<xref rid="R13" ref-type="bibr">13</xref>] Soluble VEGF receptors block the downstream effects of VEGF ligands by depleting available VEGF molecules and preventing their attachment to membrane-bound VEGF receptors. Soluble VEGF-R1 has a high affinity to VEGF-A and is postulated to mediate corneal avascularity during development.[<xref rid="R14" ref-type="bibr">14</xref>] The presence of corneal insult or inflammation disrupts the equilibrium by upregulating proangiogenic factors and downregulating antiangiogenic agents, leading to corneal hemangiogenesis and lymphangiogenesis.</p><p>LSCD, a consequence of a dysfunctional limbal stem cell (LSC) population, can also lead to CoNV. LSC has the unique capacity to differentiate into normal corneal epithelial cells. Any damage in LSC leads to cellular apoptosis followed by replacement with abnormal conjunctival epithelial cells. Corneal stem cells play a vital role in maintaining the integrity of corneal surface. When these stem cells are damaged or deficient, the corneal surface becomes compromised, leading to the loss of barrier function that normally prevents blood vessels from growing into the cornea.[<xref rid="R15" ref-type="bibr">15</xref>] In LSCD, there is often an increase in inflammatory mediators such as cytokines and growth factors. These mediators create a proinflammatory environment in the cornea, promoting the infiltration of immune cells, which, in turn, release angiogenic factors promoting CoNV.[<xref rid="R16" ref-type="bibr">16</xref>] LSCD occurs when there are alterations in corneal tissue homeostasis due to depletion of LSC (such as in chemical injuries and mechanical trauma), absence of LSC (congenital aniridia), or in proinflammatory states (Steven&#x02013;Johnson syndrome or contact lens&#x02013;related hypoxia).[<xref rid="R17" ref-type="bibr">17</xref>]</p></sec><sec id="sec2-2"><title>Therapeutic approaches</title><p>Several treatment modalities have been derived based on the understanding of CoNV pathogenesis. Broadly, they can be categorized based on their mechanism of action. These include anti-inflammatory agents, anti-VEGF agents, and surgical vessel occlusion with laser or diathermy. Contemporary and experimental therapies such as gene therapy and nano-based drug therapy show promise in managing CoNV, but lack clinical studies to support their safety and efficacy. Treatment modalities studied in the literature are summarized in <xref rid="IJO.IJO_3043_23-T1" ref-type="table">Tables 1</xref>&#x02013;3. Key therapeutic approaches are evaluated below.</p><table-wrap position="float" id="IJO.IJO_3043_23-T1"><label>Table 1</label><caption><p>Summary of anti-inflammatory and anti-VEGF agents studied for corneal neovascularization</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Agent</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Level of Evidence</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mechanism of Action</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Efficacy and Remarks</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Studies</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Anti-Inflammatory</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Corticosteroids</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal studies<break/>Prospective Clinical Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibit phospholipase A2<break/>Inhibit proliferation and migration of vascular endothelial cells</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Low-cost, highly accessible<break/>Limited regression of mature CoNV<break/>More effective if started early after CoNV develops</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Hos <italic toggle="yes">et al</italic>., 2011,[<xref rid="R120" ref-type="bibr">120</xref>] Hoffart<break/><italic toggle="yes">et al</italic>., 2010[<xref rid="R22" ref-type="bibr">22</xref>]<break/>Human: Cursiefen <italic toggle="yes">et al</italic>., 2001[<xref rid="R20" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Long-term use associated with side effects such as<break/>infection and glaucoma</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NSAIDs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of COX-1/2 enzymes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Differential effectiveness; COX-2 selective inhibitors (celecoxib, rofecoxib) have limited inhibition of VEGF production</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Cooper <italic toggle="yes">et al</italic>., 1980,[<xref rid="R121" ref-type="bibr">121</xref>]<break/>Pakneshan <italic toggle="yes">et al</italic>., 2008[<xref rid="R122" ref-type="bibr">122</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Long-term use is associated with side effects such as corneal ulceration and melting</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Generally ineffective in treating CoNV</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cyclosporine A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Randomized Controlled Clinical Trial</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Calcineurin inhibitor, limits T-Cell response<break/>Inhibition of VEGF- induced primary endothelial angiogenesis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Topical, subconjunctival, and systemic administration has shown to be effective in inhibiting CoNV in experimental models<break/>Inhibitory effect of topical cyclosporine A was found to be significantly more effective than bevacizumab in an immune-mediated rabbit CoNV model</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Bucak <italic toggle="yes">et al</italic>., 2013,[<xref rid="R26" ref-type="bibr">26</xref>] Ulusoy <italic toggle="yes">et al</italic>., 2020[<xref rid="R123" ref-type="bibr">123</xref>]<break/>Human:<break/>Bock <italic toggle="yes">et al</italic>., 2014[<xref rid="R27" ref-type="bibr">27</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Limited inhibition of CoNV in post-keratoplasty patients</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tacrolimus</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Immunosuppressor, calcineurin inhibitor that suppresses T-cell/B-cell activation and proliferation</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Subconjunctival tacrolimus was shown to be more effective than anti-rat- VEGF in an alkali-burn rat model<break/>Topical application is limited by its poor corneal permeability</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Chen <italic toggle="yes">et al</italic>., 2018[<xref rid="R31" ref-type="bibr">31</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Methotrexate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anti-metabolite; Mechanism not well understood<break/>Anti-inflammatory response through reduction of chemokine- induced VCAM</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Topical and subconjunctival administration effective in suture-induced CoNV rabbit models with associated reduction of VEGF and IL-6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Byun <italic toggle="yes">et al</italic>., 2011[<xref rid="R124" ref-type="bibr">124</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anti-angiogenesis associated with inhibition of VEGF and bFGF, similar to thalidomide</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thalidomide/Thalidomide Analogue (CC-3052)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of VEGF, FGF-2, and TNF-&#x003b1;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effective inhibition of CoNV in experimental models, however, special caution should be exercised regarding dosage safety and efficacy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Kruse <italic toggle="yes">et al</italic>., 1998,[<xref rid="R125" ref-type="bibr">125</xref>] Abbas <italic toggle="yes">et al</italic>., 2002,[<xref rid="R126" ref-type="bibr">126</xref>]<break/>Lee <italic toggle="yes">et al</italic>., 2013[<xref rid="R127" ref-type="bibr">127</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Side effects appear to be lower with thalidomide analogues (teratogenicity)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin Receptor Inhibitors (IL-1ra, IL-17 mAb, tocilizumab)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of pro- angiogenic activity of Interleukins<break/>Promote angiogenesis either directly &#x02013; activation of endothelial cells, or indirectly &#x02013; macrophage polarization and VEGF secretion</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IL-1ra was associated with significant inhibition of CoNV in early initiation of therapy after induction of CoNV in a murine model<break/>Efficacy of CoNV inhibition in subconjunctival tocilizumab was comparable to that of bevacizumab in a suture- induced rabbit model</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Dana <italic toggle="yes">et al</italic>., 1998,[<xref rid="R128" ref-type="bibr">128</xref>] Yoo <italic toggle="yes">et al</italic>., 2014[<xref rid="R35" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1; Inhibitors (Infliximab, Enterecept, adalimumab)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of TNF-&#x003b1;, a pro- inflammatory cytokine responsible for corneal lymphangiogenesis through the induction of VEGF-C production by macrophages<break/>TNF-&#x003b1; is also responsible<break/>for the expression of angiogenic factors</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Experimental models displayed the inhibitory effects of TNF-&#x003b1; Inhibitors on CoNV<break/>Effectiveness of subconjunctival etanercept is enhanced when used in conjunction with bevacizumab in a rat silver nitrate cauterization model<break/>Subconjunctival adalimumab more effectively reduced VEGF expression than bevacizumab in a rat silver/potassium nitrate<break/>cauterization model</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Ozdemir <italic toggle="yes">et al</italic>., 2013,[<xref rid="R34" ref-type="bibr">34</xref>] &#x000d6;zkaya <italic toggle="yes">et al</italic>., 2023[<xref rid="R129" ref-type="bibr">129</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Tyrosine Kinase Inhibitors (Sorafenib, Semaxanib, Rivoceranib, Regorafenib, Lapatinib, Axitinib, Dovitinib, Dasatinib, Sunitinib, Vatalanib, Nilotinib, Pazopanib, ZK261991, AG 1296)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Prospective Clinical Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Multitarget/Selective TKI in signaling pathways</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effectiveness comparable to corticosteroids and anti- VEGF<break/>Requires further evaluation of therapeutic effect and long-term safety in clinical studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Onder <italic toggle="yes">et al</italic>., 2014[<xref rid="R36" ref-type="bibr">36</xref>]<break/>Human: Amparo <italic toggle="yes">et al</italic>., 2013[<xref rid="R130" ref-type="bibr">130</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">Transforming growth factor-&#x003b2;-activated kinase 1 (5Z-7-oxozeaenol)</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="3" colspan="1">Animal Studies</td><td align="left" rowspan="3" colspan="1"/><td align="left" rowspan="3" colspan="1">Inhibits cell proliferation via suppression of cell cycle and DNA replication<break/>Inhibition of TNF&#x003b1;- mediated NF&#x003ba;B signaling</td><td align="left" rowspan="3" colspan="1"/><td align="left" rowspan="1" colspan="1">Topical administration of 5Z-7-oxozeaenol suppresses corneal neovascularization in a mouse model</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="3" colspan="1">Animal:<break/>Wang <italic toggle="yes">et al</italic>., 2022[<xref rid="R131" ref-type="bibr">131</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">Effect is enhanced when gelatin- nanoparticles- encapsulated 5Z-7- oxozeaenol are administered, likely due to the extended retention of the drug in the cornea</td><td align="left" rowspan="2" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Anti-VEGF</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="5" colspan="1">Bevacizumab</td><td align="left" rowspan="5" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Humanized anti-VEGF-A monoclonal antibody</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="3" colspan="1">Prolonged topical use associated with loss of integrity of corneal epithelium</td><td align="left" rowspan="3" colspan="1"/><td align="left" rowspan="2" colspan="1">Animal:<break/>Manzano <italic toggle="yes">et al</italic>., 2007[<xref rid="R43" ref-type="bibr">43</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">Randomized Controlled Clinical Trials</td><td align="left" rowspan="3" colspan="1"/><td align="left" rowspan="4" colspan="1">Large molecular weight and size may impede corneal penetrance</td><td align="left" rowspan="4" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Human:</td></tr><tr><td align="left" rowspan="2" colspan="1">Pooled meta-analysis suggests significant inhibitory effects of topical and subconjunctival bevacizumab on CoNV in both human and animal studies</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">Dastjerdi <italic toggle="yes">et al</italic>., 2010,[<xref rid="R132" ref-type="bibr">132</xref>]<break/>Petsoglou <italic toggle="yes">et al</italic>., 2013,[<xref rid="R133" ref-type="bibr">133</xref>]<break/>Papathanassiou <italic toggle="yes">et al</italic>., 2013[<xref rid="R48" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Meta-analysis</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ranibizumab</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Prospective Clinical Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Recombinant humanized anti-VEGF-A monoclonal antibody<break/>Lower molecular weight and size allows greater drug penetration than bevacizumab</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effectiveness in inhibiting CoNV in comparison to bevacizumab remains inconclusive, but ranibizumab appears to induce neovascular reduction earlier than bevacizumab in animal models</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Kim <italic toggle="yes">et al</italic>., 2014,[<xref rid="R134" ref-type="bibr">134</xref>]<break/>Liarakos <italic toggle="yes">et al</italic>., 2014[<xref rid="R51" ref-type="bibr">51</xref>]<break/>Human:<break/>Kim <italic toggle="yes">et al</italic>., 2013,[<xref rid="R52" ref-type="bibr">52</xref>] Ferrari <italic toggle="yes">et al</italic>., 2013[<xref rid="R49" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Topical ranibizumab was found to inhibit CoNV mostly through the reduction of vessel caliber rather than invasion area Comparative inhibitory effect of ranibizumab and bevacizumab in clinical studies remains to be<break/>further validated</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Pegaptanib</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">Animal Studies</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">Oligonucleotide aptamer that selectively binds VEGF-165</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1">Inconclusive treatment efficacy in both topical and subconjunctival administration in experimental animal models No inhibitory effect on corneal neovascularization was noted in a rabbit model when compared to topical prednisolone</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:</td></tr><tr><td align="left" rowspan="1" colspan="1">Akar <italic toggle="yes">et al</italic>., 2013,[<xref rid="R39" ref-type="bibr">39</xref>] Andrade <italic toggle="yes">et al</italic>., 2021[<xref rid="R53" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Aflibercept</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Prospective Clinical Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Humanized recombinant fusion protein that binds VEGF and PlGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inconclusive treatment efficacy in both topical and subconjunctival administration in comparison to other anti- VEGFs in animal models<break/>No significant improvement of corneal neovascularization following subconjunctival administration of aflibercept in six patients</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Oliveira <italic toggle="yes">et al</italic>., 2010,[<xref rid="R135" ref-type="bibr">135</xref>] Eski <italic toggle="yes">et al</italic>. 2022[<xref rid="R136" ref-type="bibr">136</xref>]<break/>Human:<break/>Sella <italic toggle="yes">et al</italic>., 2021[<xref rid="R58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Conbercept</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Case Series Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Humanized recombinant fusion protein that binds specifically to VEGF-B, PlGF and various isoforms of VEGF-A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Topical, subconjunctival, and intrastromal conbercept was found to have statistically significant effect on CoNV regression in rabbit models</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Liu <italic toggle="yes">et al</italic>., 2020,[<xref rid="R137" ref-type="bibr">137</xref>] Du <italic toggle="yes">et al</italic>., 2023[<xref rid="R138" ref-type="bibr">138</xref>]<break/>Human:<break/>Sun <italic toggle="yes">et al</italic>., 2023[<xref rid="R139" ref-type="bibr">139</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effectiveness of CoNV inhibition has yet to be compared to alternative anti-VEGFs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Laser Photocoagulation</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Prospective Clinical Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Heat-induced photocoagulation of corneal vasculature</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">More commonly used in chronic CoNV, in part due to the limited efficacy of medical therapies on more established corneal vasculature<break/>Repeated treatments are often required due to recanalization of corneal vessels<break/>May cause damage of surrounding tissues</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Cherry <italic toggle="yes">et al</italic>., 1976[<xref rid="R140" ref-type="bibr">140</xref>]<break/>Human:<break/>Gordon <italic toggle="yes">et al</italic>., 2002,[<xref rid="R141" ref-type="bibr">141</xref>] Kumar <italic toggle="yes">et al</italic>., 2016[<xref rid="R77" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Photodynamic Therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Prospective Clinical Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Excitation of photosensitizers to occlude corneal vessels through thrombus formation</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Relatively selective for corneal neovascular vessels with little damage to surrounding tissue<break/>Repeated treatments are often required for extensive disease<break/>High costs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Primbs <italic toggle="yes">et al</italic>., 1998[<xref rid="R142" ref-type="bibr">142</xref>]<break/>Human:<break/>Al-Torbak <italic toggle="yes">et al</italic>., 2012,[<xref rid="R143" ref-type="bibr">143</xref>] Yoon <italic toggle="yes">et al</italic>., 2007[<xref rid="R144" ref-type="bibr">144</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Fine Needle Diathermy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Prospective Clinical Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Coagulating current used to occlude corneal vessels</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">More effective than topical dexamethasone in mature CoNV and lymphatics regression in a sutured- induced CoNV mouse model<break/>Corneal vascularization secondary to thermal<break/>cautery may be reduced with combined anti-VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Le <italic toggle="yes">et al</italic>., 2018[<xref rid="R85" ref-type="bibr">85</xref>]<break/>Human:<break/>Romano <italic toggle="yes">et al</italic>., 2016,[<xref rid="R145" ref-type="bibr">145</xref>] Pillai <italic toggle="yes">et al</italic>., 2000[<xref rid="R80" ref-type="bibr">80</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="TF-F1"><p>Legend: CoNV, Corneal Neovascularization; NSAID, Non-Steroidal Anti-Inflammatory Drug; COX; Cyclooxygenase, VEGF, Vascular Endothelial Growth Factor; IL, Interleukin; VCAM, Vascular Cell Adhesion Molecule; FGF, Fibroblast Growth Factor; TNF, Tumor Necrosis Factor; IL-1ra, Interleukin-1 Receptor Antagonist; IL-17 mAb, Interleukin-17 Monoclonal Antibody; TKI, Tyrosine Kinase Inhibitors; PlGF, Placental Growth Factor; Nuclear Factor-&#x003ba;B, NF&#x003ba;B</p></fn></table-wrap-foot></table-wrap><sec id="sec3-1"><title>Anti-inflammatory agents</title><p>Inflammation is a key driver of corneal angiogenesis and is mediated by the release of proangiogenic cytokines such as IL-1, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and VEGF.[<xref rid="R18" ref-type="bibr">18</xref>]</p><p>Corticosteroids are potent inhibitors of inflammation and remain widely accepted as first-line therapy for CoNV. By inhibiting vascular endothelial cells, steroids may exert a direct antiangiogenic effect through inhibition of VEGF expression from the vascular smooth muscle cells.[<xref rid="R19" ref-type="bibr">19</xref>] They also inhibit the migration of inflammatory cells, such as macrophages and lymphocytes, into the cornea. Inflammatory cells release angiogenic factors that promote neovascularization. By limiting the infiltration of these cells, steroids indirectly inhibit the growth of new blood vessels. Furthermore, steroids stabilize newly formed blood vessels, making them less fragile and less prone to leakage. This stabilization effect can prevent further expansion of the abnormal corneal vascular complex. However, their antiangiogenic effects are weak and insufficient to induce regression of long-term, mature CoNVs.[<xref rid="R20" ref-type="bibr">20</xref>]</p><p>The efficacy of steroids in suppressing angiogenesis is maximized if they are started immediately following corneal insult. Delays in administration may render them ineffective against subsequent development of CoNV.[<xref rid="R21" ref-type="bibr">21</xref>] In a chemical cauterization rat model, early and immediate application of dexamethasone resulted in a significant reduction of new vessel size compared to the control group.[<xref rid="R22" ref-type="bibr">22</xref>] Roshandel <italic toggle="yes">et al</italic>. have suggested prompt and aggressive treatment of CoNV associated with inflammatory conditions such as herpes simplex virus, immune stromal keratitis, and corneal graft rejection with early, frequent corticosteroids, before tapering them slowly based on clinical response.[<xref rid="R23" ref-type="bibr">23</xref>] However, the optimal duration of treatment remains controversial. Cursiefen <italic toggle="yes">et al</italic>.[<xref rid="R20" ref-type="bibr">20</xref>] showed that there was no difference in CoNV extent between post-keratoplasty patients who received either 6 months or 12 months of topical steroid therapy. Long-term corticosteroid usage is also associated with ocular and systemic side effects.[<xref rid="R24" ref-type="bibr">24</xref>] Despite this, corticosteroids remain the mainstay of treatment due to their low cost, accessibility, and anti-inflammatory properties.</p><p>Cyclosporine is an immunomodulatory agent which inhibits the migration of primary endothelial cells. The mechanism behind its antiangiogenic effects are not well characterized, but is thought to be related to an overexpression of HESR1 transcription factor and a downregulation of VEGF-R2.[<xref rid="R25" ref-type="bibr">25</xref>] The role of cyclosporine in the treatment of CoNV remains controversial as conflicting evidence on its efficacy have been reported. In one study, topical cyclosporine A 0.05% was found to be more effective than topical bevacizumab 0.5% (24.4% vs. 37.1%, <italic toggle="yes">P</italic> = 0.03) but less effective than topical dexamethasone 0.1% (24.4% vs. 5.9%, <italic toggle="yes">P</italic> = 0.02) in reducing the extent of neovascularization in a rabbit cornea model.[<xref rid="R26" ref-type="bibr">26</xref>] On the contrary, a randomized, prospective, multicenter clinical trial did not find any significant difference in the incidence of CoNV following high-risk keratoplasty among patients receiving either 5.13 or 7.7 mg subconjunctival cyclosporine A implant when compared to placebo.[<xref rid="R27" ref-type="bibr">27</xref>] This was postulated to be related to the strong proangiogenic stimulus after high-risk transplantation and poor drug penetration into the anterior chamber following local administration of cyclosporine.[<xref rid="R28" ref-type="bibr">28</xref>]</p><p>Tacrolimus is a calcineurin inhibitor which decreases T-cell activation and inflammatory cytokine release. It has a higher potency than cyclosporine, exhibiting similar effects at concentrations 100 times lower.[<xref rid="R29" ref-type="bibr">29</xref>] It reduces the production of angiogenic factors such as VEGF, epidermal growth factor, platelet-derived growth factor, prostaglandin E2, TNF-&#x003b1;, MMP-9, MMP-13, IL-1, IL-6, and hypoxia-inducible factor.[<xref rid="R30" ref-type="bibr">30</xref>] In a corneal alkali burn model, topical tacrolimus 0.05% administered four times daily was more effective than subconjunctival anti-rat-VEGF (0.5 mg/0.05 ml) in decreasing CoNV after 1 month of therapy.[<xref rid="R31" ref-type="bibr">31</xref>] Corneal epithelial defects and opacities were also significantly reduced by topical tacrolimus. However, the efficacy of topically instilled tacrolimus is limited by poor drug penetration across the cornea.[<xref rid="R32" ref-type="bibr">32</xref>] Cationic liposomal tacrolimus has been reported to be effective in circumventing this problem. With a surface potential of approximately +30 mV, this formulation binds to the negatively charged mucin layer of the ocular surface to increase the concentration of tacrolimus in the anterior chamber of mice by 20-fold at 90 min post-instillation.[<xref rid="R32" ref-type="bibr">32</xref>] Furthermore, this new drug delivery vehicle was more effective than topical tacrolimus in inhibiting CoNV, reducing corneal inflammation, and shortening the duration required for corneal epithelial recovery. However, adherence of topical tacrolimus may be an issue. Some patients may experience temporary discomfort, burning, or stinging in the eyes after applying tacrolimus ointment. Tacrolimus ointment might exacerbate dry eye symptoms in some individuals. Prolonged use of topical tacrolimus may also increase the risk of ocular infection because of local immunosuppression.[<xref rid="R33" ref-type="bibr">33</xref>]</p><p>Immunomodulatory biologic therapies including IL-6 receptor antagonist, tyrosine kinase inhibitors, and TNF-&#x003b1; inhibitors have been shown in experimental studies to be effective in treating CoNV.[<xref rid="R34" ref-type="bibr">34</xref><xref rid="R35" ref-type="bibr">35</xref><xref rid="R36" ref-type="bibr">36</xref>] Subconjunctival tocilizumab, an IL-6 receptor antagonist, was as effective as subconjunctival bevacizumab in reducing the extent of CoNV.[<xref rid="R35" ref-type="bibr">35</xref>] Subconjunctival sunitinib, a tyrosine kinase inhibitor, reduced neovascularization area in experimental rat corneas at a level comparable to subconjunctival bevacizumab.[<xref rid="R37" ref-type="bibr">37</xref>] Subconjunctival etanercept, a recombinant TNF receptor which antagonizes both TNF-&#x003b1; and TNF-&#x003b2;, demonstrated anti-inflammatory and antiangiogenic effects in an animal model, and the effects were further enhanced when given in conjunction with subconjunctival bevacizumab.[<xref rid="R34" ref-type="bibr">34</xref>] However, further human clinical studies are required to ascertain their clinical safety and utility.</p></sec><sec id="sec3-2"><title>Anti-vascular endothelial growth factor</title><p>Anti-VEGF agents such as pegaptanib, bevacizumab, ranibizumab, and aflibercept have been administered off-label, via topical, subconjunctival, and intrastromal routes, to treat CoNV.[<xref rid="R38" ref-type="bibr">38</xref><xref rid="R39" ref-type="bibr">39</xref><xref rid="R40" ref-type="bibr">40</xref><xref rid="R41" ref-type="bibr">41</xref>] Among the anti-VEGF agents, bevacizumab is most commonly used to treat neovascular age-related macular degeneration and diabetic macular edema due to its widespread availability and cost-effectiveness. Bevacizumab is a large, full-length humanized monoclonal antibody that binds to all isoforms of VEGF-A. Owing to its large molecular weight of 149 kD, it is typically unable to penetrate the cornea. However, in experimental animal models, the pathologically vascularized stroma permits penetration of large immunoglobulin molecules and increases the viability of topical administration.[<xref rid="R42" ref-type="bibr">42</xref>] In a rat model of chemically induced CoNV, topical bevacizumab 4 mg/ml drops administered twice daily for 1 week was demonstrably more effective than placebo in reducing the area of CoNV (38.2% vs. 63.5%, <italic toggle="yes">P</italic> &#x0003c; 0.02).[<xref rid="R43" ref-type="bibr">43</xref>] A prospective clinical trial of short-term topical bevacizumab 10 mg/ml eyedrops administered two to four times daily for 3 weeks successfully reduced the area of neovascularization (47.5%, <italic toggle="yes">P</italic> &#x0003c; 0.001) and diameter of neovascular vessels (36.2%, <italic toggle="yes">P</italic> = 0.003) at 6 months.[<xref rid="R44" ref-type="bibr">44</xref>] Although no adverse ophthalmic or systemic events were reported, this study excluded patients with poor corneal epithelial integrity (either existing epithelial defects or previous corneal surgeries) and utilized a shorter treatment course with a lower concentration of topical bevacizumab, compared to other studies. In contrast, separate studies have reported corneal epitheliopathy, approaching 60% of the eyes which received topical bevacizumab 12.5 mg/ml over the course of 3 months, and development of epithelial defects in 16.7% of eyes after administration of topical bevacizumab 5 mg/ml for up to 1 year of therapy.[<xref rid="R45" ref-type="bibr">45</xref><xref rid="R46" ref-type="bibr">46</xref>] Both studies reported improvements in CoNV parameters. Despite improvements in neovascularization, there was no statistically significant improvement in visual acuity.[<xref rid="R43" ref-type="bibr">43</xref><xref rid="R45" ref-type="bibr">45</xref><xref rid="R46" ref-type="bibr">46</xref>]</p><p>Subconjunctival bevacizumab (2.5 mg/0.1 ml) administered monthly for up to 3 months in patients with CoNV has been demonstrated to reduce the extent and density of neovascular vessels (6.0 &#x000b1; 1.2 clock hours before and 4.6 &#x000b1; 1.0 clock hours after bevacizumab injection, <italic toggle="yes">P</italic> = 0.008).[<xref rid="R47" ref-type="bibr">47</xref>] A meta-analysis of seven clinical trials of subconjunctival bevacizumab showed a pooled reduction of 32% (95% confidence interval [CI]: 10%&#x02013;54%) in the neovascularization area.[<xref rid="R48" ref-type="bibr">48</xref>] The pooled mean change in best corrected visual acuity in three eligible studies demonstrated a mean improvement of 0.04 log of minimum angle of resolution (logMAR; 95% CI: -0.01&#x02013;0.09), but this improvement was not statistically significant. The analyses were limited by substantial heterogeneity among the studies (studies for neovascularization area: <italic toggle="yes">I</italic><sup>2</sup> = 92.8%, best correct visual acuity: <italic toggle="yes">I</italic><sup>2</sup> = 73%). Interestingly, this meta-analysis demonstrated that the efficacy of subconjunctival bevacizumab was comparable to that of topical bevacizumab, although this was limited by the small population and large heterogeneity between the studies.</p><p>Ranibizumab is a recombinant humanized monoclonal antibody that is affinity-matured to optimize VEGF-A binding potential. It has a smaller molecular weight of 48 kD, which theoretically allows better penetration of the cornea than bevacizumab. Topical administration of ranibizumab 10 mg/ml four times daily for 3 weeks has been reported to reduce the neovascularization extent (55.3%, <italic toggle="yes">P</italic> &#x0003c; 0.001) and the diameter of neovascular vessels (59%, <italic toggle="yes">P</italic> &#x0003c; 0.001) at 4 months.[<xref rid="R49" ref-type="bibr">49</xref>] Similar to studies on topical bevacizumab, there were no statistically significant changes in invasion area or visual acuity. No adverse ophthalmic or systemic events were reported, though patients with previous ocular surgery or corneal epithelial defects were excluded from the study. Comparison of the bevacizumab and ranibizumab studies with similar study population characteristics by Cheng <italic toggle="yes">et al</italic>. and Ferrari <italic toggle="yes">et al</italic>. demonstrated earlier improvements in vessel caliber and neovascularization area in the topical ranibizumab group, likely attributable to the smaller molecular size.[<xref rid="R50" ref-type="bibr">50</xref>] However, there were no statistically significant differences in neovascularization area, vessel caliber, or invasion area between the two medications at the study endpoint.</p><p>Subconjunctival and intrastromal administration of ranibizumab has also been investigated as a potential therapeutic option. In rabbit cornea models, subconjunctival ranibizumab (1 mg/0.1 ml) administered 1 h after alkali burns resulted in smaller vascularization areas at 2 weeks (control: 22.63 &#x000b1; 4.03% vs. treated: 6.13 &#x000b1; 4.22%, <italic toggle="yes">P</italic> = 0.001).[<xref rid="R51" ref-type="bibr">51</xref>] VEGF levels were also significantly lower in all the sampled anterior segment tissues including the cornea, iris, aqueous humor, and conjunctiva. The extent of cornea scarring area was, however, similar to the ranibizumab-treated and control corneas. A clinical randomized prospective study of 16 patients with chronic CoNV demonstrated that combined subconjunctival and intrastromal bevacizumab (2.5 mg/0.1 ml) and ranibizumab (1 mg/0.1 ml) both reduced the neovascularization area at 1 month.[<xref rid="R52" ref-type="bibr">52</xref>] Notably, bevacizumab resulted in greater reduction in neovascularization area compared to ranibizumab (28.4 &#x000b1; 9.01% vs. 4.51 &#x000b1; 11.64%, <italic toggle="yes">P</italic> = 0.001). Further prospective randomized controlled trials with larger study populations will be required to provide evidence on the long-term efficacy of bevacizumab versus ranibizumab.</p><p>Pegaptanib is an oligonucleotide aptamer that selectively binds to VEGF-165. It has shown variable efficacy in treating CoNV in animal models. Topical 0.5% and 1.0% pegaptanib sodium diluted in 15 ml of 0.5% carboxymethylcellulose sodium were both less effective than topical 1.0% prednisolone acetate in reducing neovascularization area, total vascular length, and number of neovascular vessels in a rabbit alkali burn model.[<xref rid="R53" ref-type="bibr">53</xref>] Another experimental rat model investigating the efficacy of subconjunctival bevacizumab, ranibizumab, and pegaptanib found that all three agents reduced the area of neovascularization, but bevacizumab produced a larger area of reduction compared to ranibizumab and pegaptanib.[<xref rid="R39" ref-type="bibr">39</xref>]</p><p>Aflibercept is a soluble fusion protein of VEGF receptors 1 and 2.[<xref rid="R54" ref-type="bibr">54</xref>] It is a relatively newer anti-VEGF compared to bevacizumab and ranibizumab, with a wider range of target molecules including VEGF-A, VEGF-B, and placental growth factor.[<xref rid="R55" ref-type="bibr">55</xref>] While an animal study showed that topical aflibercept 2 mg/0.5 ml and 2 mg/5 ml were effective in reducing neovascularization surface area, the effect was comparable to topical bevacizumab 2.5 mg/1 ml.[<xref rid="R40" ref-type="bibr">40</xref>] In another rat model of chemically induced CoNV, subconjunctival administration of bevacizumab (1.25 mg/0.05 ml) or ranibizumab (0.5 mg/0.05 ml) or aflibercept (1.25 mg/0.05 ml) was effective in inhibiting CoNV, inflammation, fibroblast activity, and reduced VEGF levels in neovascularized arteries.[<xref rid="R56" ref-type="bibr">56</xref>] No significant differences in efficacy were noted among the three medications. A comparison of topical aflibercept and topical bevacizumab in corneal chemical burn rat models demonstrated smaller areas of neovascularization at day 7 and day 10 in rat corneas receiving topical aflibercept compared to topical bevacizumab (aflibercept: 21.73 &#x000b1; 14.59% on day 7 and 31.0 &#x000b1; 23.61% on day 10 vs. bevacizumab: 51.27 &#x000b1; 15.50% on day 7 and 54.4 &#x000b1; 11.33% on day 10, <italic toggle="yes">P</italic> &#x0003c; 0.001).[<xref rid="R57" ref-type="bibr">57</xref>] Clinically, a single subconjunctival injection with 0.08 ml of aflibercept (25 mg/ml) in six eyes with CoNV did not demonstrate significant changes in the extent, density, or centricity of corneal blood vessels up to 3 months after treatment.[<xref rid="R58" ref-type="bibr">58</xref>] Further studies are required to ascertain the effectiveness of pegaptanib and aflibercept in treating CoNV.</p><p>Intrastromal anti-VEGF therapy was proposed as a more effective drug administration route for CoNV due to the delayed drug elimination from the avascular cornea. Multiple case series and clinical studies have demonstrated the efficacy of intrastromal injections in regression of neovascularization and sustained reduction of VEGF levels.[<xref rid="R59" ref-type="bibr">59</xref><xref rid="R60" ref-type="bibr">60</xref><xref rid="R61" ref-type="bibr">61</xref><xref rid="R62" ref-type="bibr">62</xref>] In a suture-induced rabbit cornea neovascularization model, intrastromal bevacizumab (1.25 mg/0.05 ml) and intrastromal aflibercept (2 mg/0.05 ml) reduced CoNV more effectively at 2 weeks (88.1% and 82.5%, respectively) compared to subconjunctival bevacizumab (1.25 mg/0.05 ml) or subconjunctival aflibercept (2 mg/0.05 ml) (64.5% and 69.9%, respectively).[<xref rid="R41" ref-type="bibr">41</xref>] However, intrastromal injections may be associated with procedural complications such as Descemet&#x02019;s membrane perforation or detachment.</p><p>Complications associated with topical anti-VEGF therapy include corneal wound healing impairment that manifests as persistent epithelial defects and corneal stromal thinning.[<xref rid="R45" ref-type="bibr">45</xref><xref rid="R46" ref-type="bibr">46</xref><xref rid="R63" ref-type="bibr">63</xref>] A theoretical side effect is neurotrophic keratopathy due to inhibition of VEGF-mediated neural growth.[<xref rid="R64" ref-type="bibr">64</xref>] However, this has yet to be observed clinically. Risk factors for development of corneal epitheliopathy include the use of high concentrations of bevacizumab (&#x0003e;10 mg/ml), extended duration of therapy, pre-existing corneal epithelial defects, and previous corneal surgeries. No systemic complications of topical anti-VEGF, such as cerebrovascular accidents and thromboembolic events, have been reported in the limited number of clinical studies published to date. Nonetheless, it is prudent to take precautions to reduce systemic absorption of the drug, such as performing punctal occlusion or applying punctal plugs before topical administration.[<xref rid="R50" ref-type="bibr">50</xref>] Subconjunctival injection of anti-VEGF is safe and well tolerated, with no significant side effects reported in human or animal studies. Common adverse events include subconjunctival hemorrhage (28%), pain (31%), anterior chamber reaction (8%), and irritation (3%).[<xref rid="R48" ref-type="bibr">48</xref><xref rid="R65" ref-type="bibr">65</xref><xref rid="R66" ref-type="bibr">66</xref><xref rid="R67" ref-type="bibr">67</xref>]</p><p>Although current studies show promise in treating CoNV, anti-VEGF agents only produce a partial and temporary reduction in neovascularization, with most effects occurring within a month of commencing therapy with progressive waning over the subsequent 2 months.[<xref rid="R68" ref-type="bibr">68</xref>] Neovascularization may also recur after successful treatment with subconjunctival bevacizumab, necessitating repeated injections.[<xref rid="R69" ref-type="bibr">69</xref>] While there are anecdotal reports of subconjunctival bevacizumab successfully treating CoNV, these reports are rare and confounded by the concomitant or preceding administration of other therapeutics such as corticosteroids.[<xref rid="R70" ref-type="bibr">70</xref><xref rid="R71" ref-type="bibr">71</xref><xref rid="R72" ref-type="bibr">72</xref>] In addition, there is a paucity of long-term clinical outcomes, with most studies reporting follow-up of up to 3 months. The advent of new anti-VEGF drugs, such as brolucizumab and faricimab, further expands the armamentarium of therapies available. Therefore, further large-scale studies and long-term evaluation of anti-VEGF agents are required to ascertain their effectiveness and safety in treating CoNV.</p></sec><sec id="sec3-3"><title>Physical ablation of neovascular vessels</title><p>Medical therapy may have limited effectiveness in treating chronic CoNV with mature and well-established vascularization. In such cases, physical occlusion of neovascular vessels can be considered with laser photocoagulation, photodynamic therapy, or FND.</p><p>Laser photocoagulation using argon, yellow dye, and Nd:YAG neodymium:yttrium-aluminium-garnet laser has been shown to be effective in treating CoNV in animal[<xref rid="R73" ref-type="bibr">73</xref><xref rid="R74" ref-type="bibr">74</xref><xref rid="R75" ref-type="bibr">75</xref>] and clinical studies.[<xref rid="R76" ref-type="bibr">76</xref><xref rid="R77" ref-type="bibr">77</xref>] Although laser photocoagulation can obliterate efferent neovascular vessels, as they are wider and have relatively slower blood flow, it is often unable to cauterize narrower and deeper afferent vessels with faster blood flow. A single prospective study of 40 patients with CoNV receiving double-frequency Nd:YAG laser photocoagulation demonstrated improvements in the mean area of CoNV from 31.9% to 17.6% after 3 months of laser treatment.[<xref rid="R77" ref-type="bibr">77</xref>] Of 185 corneal vessels, 53.5% were completely occluded, 9.2% were partially occluded, and 37.3% were recanalized at the end of 3 months. Hence, multiple laser photocoagulation sessions may be required for patients with extensive CoNV in view of the possibility of recanalization. Side effects associated with laser photocoagulation include corneal endothelium or crystalline lens damage, corneal hemorrhage, corneal thinning, and iris atrophy.[<xref rid="R77" ref-type="bibr">77</xref>]</p><p>Photodynamic therapy achieves vessel occlusion via reactive oxygen species generation, which arise from the interaction between light energy and photosensitizers. In the treatment of CoNV, photodynamic therapy with intravenous or intrastromal verteporfin was effective in inducing angiogenic and lymphogenic regression in a rodent suture-induced CoNV model.[<xref rid="R78" ref-type="bibr">78</xref><xref rid="R79" ref-type="bibr">79</xref>] Long-term allograft survival was also improved significantly in photodynamic therapy-treated eyes when compared to controls.[<xref rid="R78" ref-type="bibr">78</xref>] A potential advantage of using photodynamic therapy is its selectivity for neovascular vessels, allowing it to induce vascular regression with minimal damage to surrounding tissues.</p><p>FND involves the use of high-frequency electrical currents to generate heat. The tip of the fine needle is heated using diathermy and subsequently applied in close proximity to the abnormal blood vessels. The heat generated coagulates the blood vessels and stops blood flow, leading to their closure.[<xref rid="R80" ref-type="bibr">80</xref>] Subsequent studies demonstrated that occlusion of corneal vessels using FND among pre-keratoplasty patients and patients with lipid keratopathy was successful in reducing lipid deposition in 82.3% of treated eyes, with 84.6% of high-risk corneal grafts surviving beyond 1 year.[<xref rid="R81" ref-type="bibr">81</xref>] Unfortunately, corneal diathermy may induce further CoNV due to thermal damage. In a mouse suture-induced CoNV model, FND monotherapy inhibited angiogenesis at early time points, but was associated with secondary corneal angiogenesis, with elevated proangiogenic factors such as VEGF-A, VEGF-C, and VEGF-D.[<xref rid="R82" ref-type="bibr">82</xref>] Hence, combination therapy with anti-VEGF agents has been proposed to complement its usage. In the same study, addition of anti-VEGF agents with FND significantly regressed corneal blood and lymphatic vessels at 1 week and prevented the undesirable effect of angiogenesis observed in the monotherapy group.[<xref rid="R82" ref-type="bibr">82</xref>] Clinically, FND combined with subconjunctival bevacizumab treatment before penetrating keratoplasty (PK) in patients with at least one quadrant of CoNV resulted in rejection-free graft survival rates of more than 90% after 1 year and 78% after 3 years.[<xref rid="R83" ref-type="bibr">83</xref>] A retrospective review of children who received FND with subconjunctival bevacizumab reported complete CoNV resolution in 88.9% within 1 month of treatment and an improvement in mean corrected distance visual acuity from 0.66 &#x000b1; 0.31 to 0.50 &#x000b1; 0.37 logMAR (<italic toggle="yes">P</italic> = 0.02).[<xref rid="R84" ref-type="bibr">84</xref>] Combination of FND and corticosteroids has also been shown to regress both blood vessels and lymphatic vessels in animal models.[<xref rid="R85" ref-type="bibr">85</xref>] However, no clinical studies are available to support the efficacy of this combination. Another strategy to reduce excessive thermal damage is to selectively cauterize afferent arterioles, which comprise &#x0003c; 1% of the neovascular vessels.[<xref rid="R86" ref-type="bibr">86</xref>] Spiteri <italic toggle="yes">et al</italic>. identified afferent neovascular vessels with fluorescein and indocyanine green corneal angiography and performed selective FND. They showed that the number of afferent vessels ranged between one and three and that the vessels had a mean diameter of 40 &#x000b5;m. After selective FND, the mean area of neovascularization was reduced by 1.80 &#x000b1; 1.40 mm<sup>2</sup> (<italic toggle="yes">P</italic> &#x0003c; 0.01) up to 12 weeks postoperatively, demonstrating the viability of this protocol in reducing CoNV while minimizing thermal damage.[<xref rid="R87" ref-type="bibr">87</xref>]</p></sec><sec id="sec3-4"><title>LSC transplantation</title><p>LSCD is an ocular surface disease caused by abnormal LSCs and can lead to CoNV. Management is challenging and medical therapy is only effective for early or partial LSCD.[<xref rid="R88" ref-type="bibr">88</xref>] Surgical management of LSCD can be categorized into allograft, autograft, and cultivated LSC transplantation. LSC grafting techniques include autologous limbal transplant, allogenic limbal transplant, keratolimbal allograft, and simple limbal epithelial transplantation (SLET). A meta-analysis of 40 studies with 2202 eyes demonstrated that autologous limbal transplantations were associated with greater visual acuity improvement (76%) than allogenic limbal transplants (52.3%), cultivated autologous LSC transplants (56.4%), and cultivated allogenic LSC transplants (43.3%) (<italic toggle="yes">P</italic> &#x0003c; 0.001).[<xref rid="R89" ref-type="bibr">89</xref>] SLET utilizes a small limbal tissue autograft that is transplanted from the healthy eye to the diseased eye.[<xref rid="R90" ref-type="bibr">90</xref>] This is accomplished by dividing the strip of donor limbal tissue into small pieces and distributing them over an amniotic membrane placed over the diseased cornea. The outcomes of SLET have been favorable and are likely comparable to those of cultivated LSCs &#x02013; 83% of reported SLET operations in the literature restored the defective corneal epithelium and 69% resulted in improvements in visual acuity.[<xref rid="R91" ref-type="bibr">91</xref>] Common complications reported in these studies following SLET include focal recurrence of LSCD, progression of conjunctivalization, progressive symblepharon, and keratitis.[<xref rid="R91" ref-type="bibr">91</xref>] No large-scale head-to-head comparison studies of SLET and other LSC transplantation techniques have been performed.</p></sec><sec id="sec3-5"><title>Mitomycin intravascular chemoembolization</title><p>Mitomycin C (MMC) intravascular chemoembolization (MICE) is an emerging technique used to treat CoNV and lipid keratopathy. MMC inhibits vascular endothelial cell proliferation and hinders neovascular vessel growth and repair.[<xref rid="R92" ref-type="bibr">92</xref>] Mimouni and Ouano described a case series of three patients who received 0.05 ml of MMC (0.4 mg/ml) injected directly into a corneal neovascular vessel.[<xref rid="R93" ref-type="bibr">93</xref>] All three patients experienced a regression of neovascularization and lipid keratopathy over a follow-up period of 1 year, with no intraoperative or postoperative complications identified. To avoid possible unwanted loss of limbal vascularization, MMC should not be injected in the direction of the limbus. Another case series reported success in inducing regression of neovascularization in two cases of MICE performed in patients with failed PK.[<xref rid="R94" ref-type="bibr">94</xref>] Further clinical studies are warranted to elucidate the long-term outcomes and safety of this treatment.</p></sec><sec id="sec3-6"><title>Corneal cross linking</title><p>Corneal cross-linking (CXL) is a procedure that utilizes ultraviolet-A (UVA) and riboflavin (vitamin B2) to treat corneal ectasias.[<xref rid="R95" ref-type="bibr">95</xref>] CXL was shown in an <italic toggle="yes">in vivo</italic> rat model to be able to temporarily suppress suture-induced corneal hemangiogenesis and lymphangiogenesis.[<xref rid="R96" ref-type="bibr">96</xref>] This is postulated to occur via the combined effects of UVA and riboflavin &#x02013; UVA irradiation has been suggested to produce an anti-lymphangiogenic effect at the cellular level, while riboflavin reduces the lipopolysaccharide-induced synthesis of inflammatory cytokines TNF-&#x003b1;, IL-1, and IL-6.[<xref rid="R97" ref-type="bibr">97</xref><xref rid="R98" ref-type="bibr">98</xref>] UVA activation of riboflavin further releases reactive oxygen species, which is theorized to reduce neovascular vessel formation.[<xref rid="R99" ref-type="bibr">99</xref>] Further short-term observations of corneal parameters in animal studies displayed a partial effectiveness in treating CoNV. Xu <italic toggle="yes">et al</italic>. studied 60 rabbits with alkali burn-induced CoNV, which were divided into six groups.[<xref rid="R100" ref-type="bibr">100</xref>] Group A (control) was not given any treatment, while groups B, C, and D received 30, 15, and 45 min of CXL immediately after injury, respectively. Groups E and F received CXL for 30 min on day 1 and 3 after the injury, respectively. CXL was performed with riboflavin 0.1% drops dissolved in dextran 20% applied every 2&#x02013;5 min for 30 min, and with continual administration during UVA irradiation once every 3 min. Irradiation with UVA was performed at an irradiance of 3 mW/cm<sup>2</sup> and a surface dose of 5.4 J/cm<sup>2</sup>. Over the course of 2 weeks, the extent of CoNV increased in a time-dependent manner across all groups. All corneas treated with CXL displayed less neovascularization than the control group, with the most significant reduction observed in corneas receiving 45 min of UVA irradiation. In a separate rabbit alkali burn model, comparison of CXL using Dresden protocol with matrix-regenerating agent also showed improvement in epithelial loss, stromal edema, corneal vascularization, and leukocytic infiltration in both groups.[<xref rid="R101" ref-type="bibr">101</xref>] CXL was, however, not able to reduce corneal opacification from alkali burns in animal models.[<xref rid="R101" ref-type="bibr">101</xref><xref rid="R102" ref-type="bibr">102</xref><xref rid="R103" ref-type="bibr">103</xref>] In a retrospective case series involving five patients, CXL was performed before or in combination with high-risk PK in patients with thin or fragile corneas. While these results may be affected by the accompanying PK, reduction of CoNV was observed in all patients (mean 70.5% &#x000b1; 22.7%) and revascularization was not observed over a mean follow-up of 16.4 weeks.[<xref rid="R104" ref-type="bibr">104</xref>] CXL remains an experimental treatment for CoNV, and additional studies relating to the optimal riboflavin dose and irradiation regimen are required.</p></sec><sec id="sec3-7"><title>Gene therapy</title><p>Gene therapy refers to the transfer of genetic material to facilitate genomic augmentation, suppression, or repair, with the aim of providing durable, long-term therapeutic expression or suppression of the edited gene.[<xref rid="R105" ref-type="bibr">105</xref>] This attempts to overcome the drawback of conventional pharmacological approaches, where the effects are temporary and require repeated treatment. Gene therapy has been studied to treat various anterior segment diseases such as dry eye disease, corneal and conjunctival scarring, epithelial wound healing, and improve corneal graft survival.[<xref rid="R106" ref-type="bibr">106</xref>]</p><p>Multiple experimental animal models targeting the angiogenic VEGF pathway via gene transfer of VEGF receptors, Flt-1 and Flk-1, have shown variable success in regressing CoNV. Gene transfer of Flt-1 using recombinant adeno-associated virus and non-viral micellar nano vectors, as well as recombinant adenovirus-mediated delivery of soluble Flk-1 produced favorable inhibition of CoNV.[<xref rid="R107" ref-type="bibr">107</xref><xref rid="R108" ref-type="bibr">108</xref><xref rid="R109" ref-type="bibr">109</xref>] Subconjunctival administration of lipoplexes carrying the VEGF and roundabout4 transcription factor, GA-binding protein gene, produced temporary improvement on CoNV.[<xref rid="R110" ref-type="bibr">110</xref>] Downregulation of VEGF via recombinant adenovirus-driven antisense VEGF RNA and nanoparticle-mediated delivery of shRNA VEGF-A plasmids reduced CoNV.[<xref rid="R111" ref-type="bibr">111</xref><xref rid="R112" ref-type="bibr">112</xref>] Techniques such as adeno-associated virus and equine infectious anemia virus-based gene therapies to upregulate the antiangiogenic factors endostatin and angiostatin to inhibit VEGF and FGF-2 were effective in suppressing CoNV, immune cell infiltration, and corneal opacification.[<xref rid="R113" ref-type="bibr">113</xref><xref rid="R114" ref-type="bibr">114</xref>] More recently, downregulation of MMP-9 using lipid nanoparticles and the use of cholesterol-modified small interfering RNA targeting stromal cell-derived factor-1 have shown promise in treating CoNV.[<xref rid="R115" ref-type="bibr">115</xref><xref rid="R116" ref-type="bibr">116</xref>] Ocular delivery of small interfering RNA via pH-sensitive vehicles had comparable efficacy to that of ranibizumab.[<xref rid="R117" ref-type="bibr">117</xref>] The only Phase III clinical gene therapy study is that of aganirsen, an antisense oligonucleotide preventing insulin receptor substrate-1 expression, which has been shown to inhibit CoNV and reduce the need for transplantation in patients with keratitis.[<xref rid="R118" ref-type="bibr">118</xref>] Aganirsen has since been granted an Orphan Drug Designation by the US Food and Drug Administration for the prevention of corneal graft rejection in 2016.</p><p>Despite advancements, more research is required to address the challenges associated with gene therapy in CoNV. Gene therapy has very limited clinical evidence available regarding its efficacy and side effects. The prominent concern relates to the risk of developing host immune responses that may lead to the generation of neutralizing antibodies against vectors carrying the therapeutic gene, which may reduce therapeutic efficacy. Another concern is the development of unwanted, &#x0201c;off-target&#x0201d; effects both locally and systemically. However, these side effects theoretically carry a lower risk in the case of corneal diseases, due to its inherent immune privilege and avascular environment. Finally, the high cost of research and development associated with gene therapy represents a major hurdle before preclinical studies can progress to clinical trials.</p></sec><sec id="sec3-8"><title>Nanoparticle-based therapy</title><p>Nanomedicine and nano-based drug delivery therapy is a new but rapidly developing field, where materials of the nanoscale are employed to enhance drug delivery to provide better therapeutic efficacy. The potential functions of nanoparticles in the treatment of CoNV are wide ranging, but can be broadly classified into three groups: (1) enhancing drug delivery via nanocarriers, (2) acting as vehicles for gene therapy, and (3) functioning as therapeutic agents.[<xref rid="R119" ref-type="bibr">119</xref>] Nanoparticle-based therapies studied in the literature are summarized in <xref rid="IJO.IJO_3043_23-T2" ref-type="table">Table 2</xref>. Notably, these therapies are still in the preclinical research stage and their clinical safety and efficacy remains to be determined. Further work is required to determine the potential toxicity of nanoparticles as well as to overcome the high cost of production associated with the large-scale production for clinical use. Nonetheless, nanoparticle-based therapy remains a promising and viable method to treat CoNV.</p><table-wrap position="float" id="IJO.IJO_3043_23-T2"><label>Table 2</label><caption><p>Summary of surgical, gene-based and nano-based delivery therapy modalities studied for corneal neovascularization</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Agent</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Level of Evidence</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mechanism of Action</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Efficacy and Remarks</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Studies</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LSC<break/>Transplantation</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies Randomized Controlled Clinical Trial Meta-analysis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Transplantation of allograft, autograft or cultivated LSC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">In a LSC deficient rabbit model, LSC with limbal stromal stem cell transplantation was significantly more effective than LSC transplantation at CoNV regression<break/>Comparative studies on the effectiveness of different graft types and transplant procedures remain inconclusive</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Zhu <italic toggle="yes">et al</italic>., 2022[<xref rid="R146" ref-type="bibr">146</xref>]<break/>Human: Zakaria <italic toggle="yes">et al</italic>., 2014,[<xref rid="R147" ref-type="bibr">147</xref>] Le <italic toggle="yes">et al</italic>., 2020[<xref rid="R148" ref-type="bibr">148</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">MICE</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Case Series</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Ablation of CNV with endothelial cell proliferation inhibition by MMC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effective in reducing corneal neovascularization in the described clinical case series<break/>Further assessment is required for the safety and efficacy of MMC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Human: Mimouni <italic toggle="yes">et al</italic>., 2022,[<xref rid="R93" ref-type="bibr">93</xref>]<break/>Addeen <italic toggle="yes">et al</italic>., 2023[<xref rid="R94" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Corneal Cross- Linking</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Case Series</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Riboflavin inhibition of TNF-&#x003b1;, IL-1, and IL-6<break/>synthesis<break/>ROS generation associated with riboflavin activation by UV-A irradiation opposes angiogenesis and lymph angiogenesis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effectiveness of CoNV inhibition observed in animal models and even in patients with progressive CoNV in need of high risk-keratoplasty<break/>Further studies on optimal dosage and regimen required</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Xu <italic toggle="yes">et al</italic>., 2018,[<xref rid="R149" ref-type="bibr">149</xref>]<break/>Kesim <italic toggle="yes">et al</italic>., 2021,[<xref rid="R150" ref-type="bibr">150</xref>]<break/>Colombo- Barboza <italic toggle="yes">et al</italic>., 2014[<xref rid="R103" ref-type="bibr">103</xref>]<break/>Human: Schaub <italic toggle="yes">et al</italic>., 2021[<xref rid="R104" ref-type="bibr">104</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Gene Therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Aganirsen</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Randomized Controlled Clinical Trial</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">IRS-1 mRNA expression inhibiting antisense oligonucleotide</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Phase III study reported safety and efficacy of aganirsen<break/>Reduced need for transplantation in viral keratitis and central corneal neovascularization</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Human: Cursiefen <italic toggle="yes">et al</italic>., 2014[<xref rid="R118" ref-type="bibr">118</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Nano-based Delivery Therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nanocomposite Hydrogels</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Different NPs embedded in hydrogels to capitalize on biomaterial properties that improve drug solubility, penetration and inhibitory effect on CoNV</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Subconjunctival injection of mesoporous silica nanoparticles integrated thermogel loaded with bevacizumab and cyclosporin showed significant inhibition of corneal neovascularization as compared to individual bevacizumab and cyclosporin therapies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Lyu <italic toggle="yes">et al</italic>., 2021[<xref rid="R151" ref-type="bibr">151</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Liposomal NP</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Phospholipid bilayer membranes capable of carrying both hydrophilic and hydrophobic molecules<break/>Enhances drug penetration and retention to improve therapeutic efficacy of vehicle drug</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Therapeutic effect and drug retention time of cationic liposomes encapsulating tacrolimus were better than commercial tacrolimus eyedrops and the free drug at CoNV inhibition</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Lin <italic toggle="yes">et al</italic>., 2021[<xref rid="R32" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Polymeric Micelles</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hydrophobic fatty acid core with a hydrophilic outer layer<break/>Smaller volume than liposomes may enhance corneal drug penetrance</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">In a corneal transplantation rat model, CoNV inhibitory effect of topical cyclosporine A micelle formulation was comparable to systemic cyclosporine A and significantly greater than the control group</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Di Tommaso <italic toggle="yes">et al</italic>., 2012[<xref rid="R152" ref-type="bibr">152</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Natural/Synthetic Polymeric NP</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Sub-micro colloidal particles formulated for enhanced drug penetration, bioavailability, biodegradability, and non-toxicity</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Kaempferol-loaded gelatin NPs was significantly more effective than kaempferol solution (poorly soluble flavonoid) at inhibiting corneal vessels formation in a mouse model<break/>In chemically induced cornea neovascularization, mice corneas treated with gp91 peptide-encapsulated gelatin nanoparticles &#x02013;an anti- angiogenic nicotinamide adenine dinucleotide phosphate oxidases</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Chuang <italic toggle="yes">et al</italic>., 2019,[<xref rid="R153" ref-type="bibr">153</xref>]<break/>Chu <italic toggle="yes">et al</italic>., 2023[<xref rid="R154" ref-type="bibr">154</xref>]<break/>Zhang <italic toggle="yes">et al</italic>., 2018[<xref rid="R155" ref-type="bibr">155</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">inhibitor, had a significant reduction in neovascular vessel area (8%) when compared to phosphate-buffered solution (34%) and gp91 (20%)<break/>Subconjunctival bevacizumab- encapsulated polylactide-co-glycolide had significantly greater inhibitory effect on corneal neovascularization than<break/>bevacizumab in an alkali burn mouse model</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Inorganic Nanoparticles</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Submicron inorganic particles utilized for drug delivery<break/>Downregulation of VEGFR-2 expression in Gold NPs Anti-inflammatory action by the ROS scavenging properties of Ce NPs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gold NP resulted in significant reduction in corneal neovascularization in a mouse model compared to control<break/>Ce NPs had comparable effectiveness in corneal neovascularization reduction to dexamethasone in an alkali mouse model<break/>Potential toxicity due to non- biodegradable nature</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Cho <italic toggle="yes">et al</italic>., 2015,[<xref rid="R156" ref-type="bibr">156</xref>]<break/>Zheng <italic toggle="yes">et al</italic>., 2019[<xref rid="R157" ref-type="bibr">157</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanoemulsions</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Immiscible oil and water layers with accompanying active surfactants that allow for enhanced stability and sustained delivery of hydrophobic drugs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">In an alkali-burn mouse model, topical application of eNano-Ro5 significantly reduced corneal neovascularization as compared to the control group, but was slightly less effective than topical dexamethasone<break/>Multicomponent nature requires extensive research and complicates manufacturing processes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Delgado- Tirado <italic toggle="yes">et al</italic>., 2022[<xref rid="R158" ref-type="bibr">158</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Dendrimers</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Polymeric NPs with a regular branched structure where surface groups can increase drug solubility and stability<break/>Modifiable chemical parameters by altering surface groups allow for further drug development</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Subconjunctival injectable dendrimer- dexamethasone gel significantly limited the extent of corneal neovascularization as compared to free dexamethasone in an alkali burn rat model</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Soiberman <italic toggle="yes">et al</italic>., 2017[<xref rid="R159" ref-type="bibr">159</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanowafers</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Nano-sized polymer with arrays of drug-filled nano reservoir to enable sustained drug release and absorption</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Axitinib nanowafer was more effective than topical axitinib in inhibiting corneal neovascularization in a murine ocular burn model</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Yuan <italic toggle="yes">et al</italic>., 2015[<xref rid="R160" ref-type="bibr">160</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="TF-F2"><p>LSC, Limbal Stem Cell; MMC, Mitomycin Intravascular Chemoembolization; MMC, Mitomycin; TNF-&#x003b1;, Tumour Necrosis Factor &#x003b1;; IL, Interleukin; ROS, Reactive; UV-A, Ultraviolet A; IRS-1, Insulin Receptor Substrate 1; mRNA, messenger Ribonucleic Acid; NP, Nanoparticle; VEGFR, Vascular Endothelial Growth Factor Receptor; Ce, Cerium oxide; eNano-Ro5, Nanoemulsion containing Ro5-3335</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="IJO.IJO_3043_23-T3"><label>Table 3</label><caption><p>Summary of other treatment modalities studied for corneal neovascularization</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Agent</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Level of Evidence</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Mechanism of Action</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Efficacy and Remarks</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Studies</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Combination Therapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Corticosteroids and Heparin</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Case Reports</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Corticosteroid inhibition of phospholipase A2 and subsequent inflammatory response</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effectiveness of combination therapy remains to be further evaluated in comparative clinical studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Nikolic <italic toggle="yes">et al</italic>., 1986,[<xref rid="R161" ref-type="bibr">161</xref>]<break/>Aydin <italic toggle="yes">et al</italic>., 2008[<xref rid="R162" ref-type="bibr">162</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mechanism of heparin in reducing neovascularization not well understood; possibly via direct modulatory effect on angiogenic growth factors, or enhancing uptake of</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Human: Tommila <italic toggle="yes">et al</italic>., 1987[<xref rid="R163" ref-type="bibr">163</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">corticosteroids into endothelial cells</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Corticosteroids and Doxycycline</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Corticosteroid inhibits phospholipase A2 and subsequent inflammatory response<break/>Doxycycline inhibits MMP</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Combination of triamcinolone acetonide and doxycycline was more effective at CoNV inhibition than the individual therapies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Aydin <italic toggle="yes">et al</italic>., 2008[<xref rid="R162" ref-type="bibr">162</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Corticosteroids and anti- VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of angiogenic factors and proinflammatory cytokines like VEGF and IL-6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effectiveness of the combination of corticosteroids and anti- VEGF did not differ significantly from individual therapeutics<break/>Remains to be further evaluated in studies with<break/>larger sample sizes and longer follow-up time</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Kang <italic toggle="yes">et al</italic>., 2010,[<xref rid="R164" ref-type="bibr">164</xref>]<break/>Hoffart <italic toggle="yes">et al</italic>., 2010[<xref rid="R22" ref-type="bibr">22</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">NSAID and anti-VEGF (Diclofenac and Bevacizumab via thermosensitive hydrogel)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dual delivery of diclofenac and bevacizumab by the thermosensitive hydrogel (Poly (dl-lactide)-poly (ethylene glycol)-poly (dl-lactide)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Proposed hydrogel caused minimal toxicity to tested cell lines at concentrations ranging from 0.05 mg/ml to 0.8 mg/ml with good ocular biocompatibility after a single subconjunctival injection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Shi <italic toggle="yes">et al</italic>., 2022[<xref rid="R165" ref-type="bibr">165</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Superior anti-angiogenic effects as compared to<break/>subconjunctival bevacizumab injection alone</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1; inhibitor and anti- VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of TNF-&#x003b1;, a pro- inflammatory cytokine responsible for corneal lymphangiogenesis through the induction of VEGF-C production by macrophages</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Simultaneous inhibition of TNF-&#x003b1; and VEGF was more effective in CoNV inhibition than monotherapies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Ozdemir <italic toggle="yes">et al</italic>.,2013,[<xref rid="R34" ref-type="bibr">34</xref>]<break/>Zhou <italic toggle="yes">et al</italic>., 2023[<xref rid="R166" ref-type="bibr">166</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TNF-&#x003b1; is also responsible for the expression of angiogenic factors</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Laser Photocoagulation and anti-VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Case Reports</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Heat-induced photocoagulation of corneal vasculature<break/>Inhibition of VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical effectiveness of the combination therapy exhibited in multiple case reports<break/>Effectiveness yet to be established in a comparative clinical study</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Human: Gerten <italic toggle="yes">et al</italic>., 2008,[<xref rid="R167" ref-type="bibr">167</xref>]<break/>Anand <italic toggle="yes">et al</italic>., 2018,[<xref rid="R168" ref-type="bibr">168</xref>]<break/>Donato <italic toggle="yes">et al</italic>., 2021[<xref rid="R169" ref-type="bibr">169</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">PDT and anti-VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Case Series Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Excitation of photosensitizers to occlude corneal vessels through thrombus formation<break/>Inhibition of VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Combination therapy was more effective than Individual monotherapies in a suture- induced rabbit model and preliminary clinical studies Anti-VEGF agents suppress VEGF release post-PDT, reducing the risk of angiogenesis and recurrence</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Kim <italic toggle="yes">et al</italic>., 2016[<xref rid="R170" ref-type="bibr">170</xref>]<break/>Human: Hamdan <italic toggle="yes">et al</italic>., 2015,[<xref rid="R171" ref-type="bibr">171</xref>] Yoon <italic toggle="yes">et al</italic>., 2019[<xref rid="R172" ref-type="bibr">172</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">FND and anti-VEGF</td><td align="left" rowspan="5" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Coagulating current used to</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">FND and bevacizumab</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:</td></tr><tr><td align="left" rowspan="1" colspan="1">Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">occlude corneal vessels</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">combination successfully</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Le <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">regressed mature CoNV in</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2020[<xref rid="R82" ref-type="bibr">82</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Case</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Inhibition of VEGF</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">patients previously</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Series</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">unresponsive to</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Human:</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">corticosteroids</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Koenig <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2012,[<xref rid="R173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Elbaz <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2015,[<xref rid="R84" ref-type="bibr">84</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mestanoglu <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2022[<xref rid="R174" ref-type="bibr">174</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Other Therapies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Descemet Membrane</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Case</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Selective removal and</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Single study revealed a</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Human:</td></tr><tr><td align="left" rowspan="2" colspan="1">Endothelial Keratoplasty</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Series</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">transplantation of Descemet</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">significant regression in</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Hayashi <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">membrane and endothelium</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">corneal neovascularization</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2021[<xref rid="R175" ref-type="bibr">175</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">postoperatively</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Mesenchymal Stem Cell Therapy</td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Source of progenitor cells</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Efficacy, bio-variability, and</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:</td></tr><tr><td align="left" rowspan="1" colspan="1">Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anti-inflammatory properties</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">safety to be further evaluated</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yao <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">in clinical studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2012,[<xref rid="R176" ref-type="bibr">176</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Song <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2018[<xref rid="R177" ref-type="bibr">177</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Tetracyclines (Doxycycline, Minocycline)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies<break/>Case<break/>Series Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">MMP and PI3K/Akt-eNOS pathway inhibition<break/>MMP, ERK1/2 and Akt pathways inhibition</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lesser side effects than Anti- VEGF and corticosteroids</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:<break/>Aydin <italic toggle="yes">et al</italic>., 2008,[<xref rid="R162" ref-type="bibr">162</xref>] Xiao<break/><italic toggle="yes">et al</italic>., 2012[<xref rid="R178" ref-type="bibr">178</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Other Antimicrobials (Tigecycline, Itraconazole, Dihydroartemisinin)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Tigecycline inhibits MMP Itraconazole inhibits cholesterol biosynthesis<break/>Dihydroartemisinin inhibits VEGF, ERK1/2 and p38 expression</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Effectiveness in CoNV inhibition displayed in experimental models<break/>Requires further evaluation of therapeutic effect in clinical studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal: Zhong <italic toggle="yes">et al</italic>., 2011,[<xref rid="R179" ref-type="bibr">179</xref>]<break/>Goktas <italic toggle="yes">et al</italic>., 2014[<xref rid="R180" ref-type="bibr">180</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Flavonoids</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anti-angiogenic properties:</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Variable effectiveness of</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:</td></tr><tr><td align="left" rowspan="1" colspan="1">(Epigallocatechin</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mechanism not well</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">individual flavonoids in</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Li <italic toggle="yes">et al</italic>,</td></tr><tr><td align="left" rowspan="1" colspan="1">Gallate, Kaempferol,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">understood, may be</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">different experimental</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2018,[<xref rid="R181" ref-type="bibr">181</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Fisetin, Luteolin,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">associated to corticosteroid-</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">models of CoNV</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Chuang <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1">Genistein, Naringenin,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">like molecular structure</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2019[<xref rid="R153" ref-type="bibr">153</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Quercetin, Coumarin</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Esculetin)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Non-Flavonoid</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Anti-angiogenic properties</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Variable bioavailability may</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:</td></tr><tr><td align="left" rowspan="1" colspan="1">Phytochemicals</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mechanism not well</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">limit the effectiveness</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Bian <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1">(Curcumin, Resveratrol,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">understood</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2008,[<xref rid="R182" ref-type="bibr">182</xref>] Kim</td></tr><tr><td align="left" rowspan="1" colspan="1">Withaferin A, Xanthatin,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic toggle="yes">et al</italic>. 2010,[<xref rid="R183" ref-type="bibr">183</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Triptolide,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thymoquinone,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Glycyrrhizin)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Vitamins</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="3" colspan="1">Suppresses angiogenic factors such as VEGF and MMP</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="3" colspan="1">Requires further evaluation of therapeutic effect in clinical studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Animal:</td></tr><tr><td align="left" rowspan="1" colspan="1">(Ascorbic Acid,</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Studies</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Suzuki <italic toggle="yes">et al</italic>.,</td></tr><tr><td align="left" rowspan="1" colspan="1">Riboflavin, 1&#x003b1;,25-</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2000,[<xref rid="R184" ref-type="bibr">184</xref>] Lee</td></tr><tr><td align="left" rowspan="1" colspan="1">dihydroxyvitamin D3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mechanism not well</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><italic toggle="yes">et al</italic>., 2012[<xref rid="R185" ref-type="bibr">185</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">understood</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF-F3"><p>MMP, Matrix Metalloproteinase; VEGF, Vascular Endothelial Growth Factor; NSAID, Non-Steroidal Anti-Inflammatory Drug; IL, Interleukin; TNF-&#x003b1;, Tumor Necrosis Factor &#x003b1;; PDT, Photodynamic Therapy; FND, Fine Needle Diathermy; PI3K/Akt-eNOS, Phosphatidylinositol 3-Kinase/Akt-endothelial Nitric Oxide Synthase; ERK1/2, Extracellular Signal-Regulated Kinase 1/2</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec sec-type="conclusion" id="sec1-2"><title>Conclusion</title><p>CoNV is a common complication of severe corneal pathologies that can result in visually significant disabilities. Recent advances in our understanding of its pathogenesis, aided by developments in imaging and pharmacological approaches, have led to the development of a range of treatment strategies. While conventional therapy has focused on reducing inflammation and targeting the VEGF pathway, an expanding array of pharmacological agents, such as tyrosine kinase inhibitors, biologic immunomodulators, and gene therapy, may be useful in improving treatment efficacy. Moreover, targeting multiple angiogenic pathways in the form of combination therapy could produce a synergistic effect and should be considered in future drug and clinical trials. However, further research, rigorous clinical trials, and long-term follow up studies are essential to refine these protocols and ensure their safety and efficacy. As our knowledge continues to expand and innovative therapies emerge, the outlook for patients with CoNV is increasingly promising.</p><sec sec-type="funding-statement" id="sec2-3"><title>Financial support and sponsorship</title><p>Nil.</p></sec><sec sec-type="COI-statement" id="sec2-4"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>We thank Yishan Wu for her assistance with the illustrative material.</p></ack><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>P</given-names></name>
<name><surname>Wang</surname><given-names>CC</given-names></name>
<name><surname>Adamis</surname><given-names>AP</given-names></name></person-group><article-title>Ocular neovascularization: An epidemiologic review</article-title><source>Surv Ophthalmol</source><year>1998</year><volume>43</volume><fpage>245</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">9862312</pub-id>
</element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sridhar</surname><given-names>MS</given-names></name></person-group><article-title>Anatomy of cornea and ocular surface</article-title><source>Indian J Ophthalmol</source><year>2018</year><volume>66</volume><fpage>190</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">29380756</pub-id>
</element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dua</surname><given-names>HS</given-names></name>
<name><surname>Faraj</surname><given-names>LA</given-names></name>
<name><surname>Said</surname><given-names>DG</given-names></name>
<name><surname>Gray</surname><given-names>T</given-names></name>
<name><surname>Lowe</surname><given-names>J</given-names></name></person-group><article-title>Human corneal anatomy redefined: A novel pre- Descemet&#x02019;s layer (Dua&#x02019;s layer)</article-title><source>Ophthalmology</source><year>2013</year><volume>120</volume><fpage>1778</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">23714320</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qazi</surname><given-names>Y</given-names></name>
<name><surname>Maddula</surname><given-names>S</given-names></name>
<name><surname>Ambati</surname><given-names>BK</given-names></name></person-group><article-title>Mediators of ocular angiogenesis</article-title><source>J Genet</source><year>2009</year><volume>88</volume><fpage>495</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">20090210</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Apte</surname><given-names>RS</given-names></name>
<name><surname>Chen</surname><given-names>DS</given-names></name>
<name><surname>Ferrara</surname><given-names>N</given-names></name></person-group><article-title>VEGF in signaling and disease: Beyond discovery and development</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>1248</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">30849371</pub-id>
</element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>A</given-names></name>
<name><surname>Nawaz</surname><given-names>MI</given-names></name></person-group><article-title>Molecular mechanism of VEGF and its role in pathological angiogenesis</article-title><source>J Cell Biochem</source><year>2022</year><volume>123</volume><fpage>1938</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">36288574</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alitalo</surname><given-names>K</given-names></name>
<name><surname>Tammela</surname><given-names>T</given-names></name>
<name><surname>Petrova</surname><given-names>TV</given-names></name></person-group><article-title>Lymphangiogenesis in development and human disease</article-title><source>Nature</source><year>2005</year><volume>438</volume><fpage>946</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16355212</pub-id>
</element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>KY</given-names></name>
<name><surname>Chang</surname><given-names>JH</given-names></name>
<name><surname>Lee</surname><given-names>H</given-names></name>
<name><surname>Azar</surname><given-names>DT</given-names></name></person-group><article-title>Proangiogenic interactions of vascular endothelial MMP14 with VEGF receptor 1 in VEGFA-mediated corneal angiogenesis</article-title><source>Invest Ophthalmol Vis Sci</source><year>2016</year><volume>57</volume><fpage>3313</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">27327585</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Webb</surname><given-names>AH</given-names></name>
<name><surname>Gao</surname><given-names>BT</given-names></name>
<name><surname>Goldsmith</surname><given-names>ZK</given-names></name>
<name><surname>Irvine</surname><given-names>AS</given-names></name>
<name><surname>Saleh</surname><given-names>N</given-names></name>
<name><surname>Lee</surname><given-names>RP</given-names></name>
<etal/></person-group><article-title>Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma</article-title><source>BMC Cancer</source><year>2017</year><volume>17</volume><fpage>434</fpage><pub-id pub-id-type="pmid">28633655</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebihara</surname><given-names>N</given-names></name>
<name><surname>Matsuda</surname><given-names>A</given-names></name>
<name><surname>Nakamura</surname><given-names>S</given-names></name>
<name><surname>Matsuda</surname><given-names>H</given-names></name>
<name><surname>Murakami</surname><given-names>A</given-names></name></person-group><article-title>Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing</article-title><source>Invest Ophthalmol Vis Sci</source><year>2011</year><volume>52</volume><fpage>8549</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">21989726</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>P</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
<name><surname>Liu</surname><given-names>G</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Mukaida</surname><given-names>N</given-names></name></person-group><article-title>Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist</article-title><source>Invest Ophthalmol Vis Sci</source><year>2009</year><volume>50</volume><fpage>4761</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19458323</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feizi</surname><given-names>S</given-names></name>
<name><surname>Azari</surname><given-names>AA</given-names></name>
<name><surname>Safapour</surname><given-names>S</given-names></name></person-group><article-title>Therapeutic approaches for corneal neovascularization</article-title><source>Eye Vis (Lond)</source><year>2017</year><volume>4</volume><fpage>28</fpage><pub-id pub-id-type="pmid">29234686</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Troyanovsky</surname><given-names>B</given-names></name>
<name><surname>Levchenko</surname><given-names>T</given-names></name>
<name><surname>M&#x000e5;nsson</surname><given-names>G</given-names></name>
<name><surname>Matvijenko</surname><given-names>O</given-names></name>
<name><surname>Holmgren</surname><given-names>L</given-names></name></person-group><article-title>Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation</article-title><source>J Cell Biol</source><year>2001</year><volume>152</volume><fpage>1247</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11257124</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ambati</surname><given-names>BK</given-names></name>
<name><surname>Nozaki</surname><given-names>M</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
<name><surname>Takeda</surname><given-names>A</given-names></name>
<name><surname>Jani</surname><given-names>PD</given-names></name>
<name><surname>Suthar</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>Corneal avascularity is due to soluble VEGF receptor-1</article-title><source>Nature</source><year>2006</year><volume>443</volume><fpage>993</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17051153</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S</given-names></name></person-group><article-title>Concise review: Limbal stem cell deficiency, dysfunction, and distress</article-title><source>Stem Cells Transl Med</source><year>2012</year><volume>1</volume><fpage>110</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23197757</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lim</surname><given-names>P</given-names></name>
<name><surname>Fuchsluger</surname><given-names>TA</given-names></name>
<name><surname>Jurkunas</surname><given-names>UV</given-names></name></person-group><article-title>Limbal stem cell deficiency and corneal neovascularization</article-title><source>Semin Ophthalmol</source><year>2009</year><volume>24</volume><fpage>139</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">19437349</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Notara</surname><given-names>M</given-names></name>
<name><surname>Alatza</surname><given-names>A</given-names></name>
<name><surname>Gilfillan</surname><given-names>J</given-names></name>
<name><surname>Harris</surname><given-names>AR</given-names></name>
<name><surname>Levis</surname><given-names>HJ</given-names></name>
<name><surname>Schrader</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>In sickness and in health: Corneal epithelial stem cell biology, pathology and therapy</article-title><source>Exp Eye Res</source><year>2010</year><volume>90</volume><fpage>188</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">19840786</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Maruyama</surname><given-names>K</given-names></name>
<name><surname>Regenfuss</surname><given-names>B</given-names></name>
<name><surname>Hos</surname><given-names>D</given-names></name>
<name><surname>Steven</surname><given-names>P</given-names></name>
<name><surname>Heindl</surname><given-names>LM</given-names></name>
<etal/></person-group><article-title>Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases</article-title><source>Prog Retin Eye Res</source><year>2013</year><volume>34</volume><fpage>89</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">23348581</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nauck</surname><given-names>M</given-names></name>
<name><surname>Karakiulakis</surname><given-names>G</given-names></name>
<name><surname>Perruchoud</surname><given-names>AP</given-names></name>
<name><surname>Papakonstantinou</surname><given-names>E</given-names></name>
<name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells</article-title><source>Eur J Pharmacol</source><year>1998</year><volume>341</volume><fpage>309</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9543253</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cursiefen</surname><given-names>C</given-names></name>
<name><surname>Wenkel</surname><given-names>H</given-names></name>
<name><surname>Martus</surname><given-names>P</given-names></name>
<name><surname>Langenbucher</surname><given-names>A</given-names></name>
<name><surname>Nguyen</surname><given-names>NX</given-names></name>
<name><surname>Seitz</surname><given-names>B</given-names></name>
<etal/></person-group><article-title>Impact of short- term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2001</year><volume>239</volume><fpage>514</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">11521696</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharif</surname><given-names>Z</given-names></name>
<name><surname>Sharif</surname><given-names>W</given-names></name></person-group><article-title>Corneal neovascularization: Updates on pathophysiology, investigations &#x00026; management</article-title><source>Rom J Ophthalmol</source><year>2019</year><volume>63</volume><fpage>15</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">31198893</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoffart</surname><given-names>L</given-names></name>
<name><surname>Matonti</surname><given-names>F</given-names></name>
<name><surname>Conrath</surname><given-names>J</given-names></name>
<name><surname>Daniel</surname><given-names>L</given-names></name>
<name><surname>Ridings</surname><given-names>B</given-names></name>
<name><surname>Masson</surname><given-names>GS</given-names></name>
<etal/></person-group><article-title>Inhibition of corneal neovascularization after alkali burn: Comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone</article-title><source>Clin Exp Ophthalmol</source><year>2010</year><volume>38</volume><fpage>346</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">21077280</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roshandel</surname><given-names>D</given-names></name>
<name><surname>Eslani</surname><given-names>M</given-names></name>
<name><surname>Baradaran-Rafii</surname><given-names>A</given-names></name>
<name><surname>Cheung</surname><given-names>AY</given-names></name>
<name><surname>Kurji</surname><given-names>K</given-names></name>
<name><surname>Jabbehdari</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Current and emerging therapies for corneal neovascularization</article-title><source>Ocul Surf</source><year>2018</year><volume>16</volume><fpage>398</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">29908870</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oray</surname><given-names>M</given-names></name>
<name><surname>Abu Samra</surname><given-names>K</given-names></name>
<name><surname>Ebrahimiadib</surname><given-names>N</given-names></name>
<name><surname>Meese</surname><given-names>H</given-names></name>
<name><surname>Foster</surname><given-names>CS</given-names></name></person-group><article-title>Long-term side effects of glucocorticoids</article-title><source>Expert Opin Drug Saf</source><year>2016</year><volume>15</volume><fpage>457</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">26789102</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>G</given-names></name>
<name><surname>Middleton</surname><given-names>FA</given-names></name>
<name><surname>Gentile</surname><given-names>KL</given-names></name>
<name><surname>Tripathi</surname><given-names>S</given-names></name>
<name><surname>Bruch</surname><given-names>D</given-names></name>
<name><surname>Maier</surname><given-names>KG</given-names></name>
<etal/></person-group><article-title>Cyclosporine inhibition of angiogenesis involves the transcription factor HESR1</article-title><source>J Surg Res</source><year>2008</year><volume>149</volume><fpage>171</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18694572</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bucak</surname><given-names>YY</given-names></name>
<name><surname>Erdurmus</surname><given-names>M</given-names></name>
<name><surname>Terzi</surname><given-names>EH</given-names></name>
<name><surname>K&#x000fc;kner</surname><given-names>A</given-names></name>
<name><surname>&#x000c7;elebi</surname><given-names>S</given-names></name></person-group><article-title>Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2013</year><volume>251</volume><fpage>2555</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">24048578</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Matthaei</surname><given-names>M</given-names></name>
<name><surname>Reinhard</surname><given-names>T</given-names></name>
<name><surname>B&#x000f6;hringer</surname><given-names>D</given-names></name>
<name><surname>Christoph</surname><given-names>J</given-names></name>
<name><surname>Ganslandt</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplasty</article-title><source>Ophthalmology</source><year>2014</year><volume>121</volume><fpage>1677</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">24780407</pub-id>
</element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Althaus</surname><given-names>C</given-names></name>
<name><surname>Dagres</surname><given-names>E</given-names></name>
<name><surname>Reinhard</surname><given-names>T</given-names></name>
<name><surname>Christians</surname><given-names>U</given-names></name>
<name><surname>Sundmacher</surname><given-names>R</given-names></name></person-group><article-title>Cyclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high- performance liquid chromatography-electrospray mass spectrometry</article-title><source>Ger J Ophthalmol</source><year>1996</year><volume>5</volume><fpage>189</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">8854101</pub-id>
</element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kino</surname><given-names>T</given-names></name>
<name><surname>Hatanaka</surname><given-names>H</given-names></name>
<name><surname>Miyata</surname><given-names>S</given-names></name>
<name><surname>Inamura</surname><given-names>N</given-names></name>
<name><surname>Nishiyama</surname><given-names>M</given-names></name>
<name><surname>Yajima</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro</article-title><source>J Antibiot (Tokyo)</source><year>1987</year><volume>40</volume><fpage>1256</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">2445722</pub-id>
</element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turgut</surname><given-names>B</given-names></name>
<name><surname>Guler</surname><given-names>M</given-names></name>
<name><surname>Akpolat</surname><given-names>N</given-names></name>
<name><surname>Dem&#x00131;r</surname><given-names>T</given-names></name>
<name><surname>Cel&#x00131;ker</surname><given-names>U</given-names></name></person-group><article-title>The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization</article-title><source>Curr Eye Res</source><year>2011</year><volume>36</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">21138364</pub-id>
</element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Zhong</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>S</given-names></name>
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Wang</surname><given-names>B</given-names></name>
<name><surname>Deng</surname><given-names>Y</given-names></name>
<etal/></person-group><article-title>The long-term effect of tacrolimus on alkali burn-induced corneal neovascularization and inflammation surpasses that of anti-vascular endothelial growth factor</article-title><source>Drug Des Devel Ther</source><year>2018</year><volume>12</volume><fpage>2959</fpage><lpage>69</lpage></element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>X</given-names></name>
<name><surname>Yu</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Sheng</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>B</given-names></name>
<etal/></person-group><article-title>Inhibition of neovascularization and inflammation in a mouse model of corneal alkali burns using cationic liposomal tacrolimus</article-title><source>Front Bioeng Biotechnol</source><year>2021</year><volume>9</volume><fpage>791954</fpage><pub-id pub-id-type="pmid">34950647</pub-id>
</element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhai</surname><given-names>LY</given-names></name>
<name><surname>Zhang</surname><given-names>XR</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Ma</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>HC</given-names></name></person-group><article-title>Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: A randomized clinical trial study</article-title><source>Eye (Lond)</source><year>2020</year><volume>34</volume><fpage>1600</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">31784702</pub-id>
</element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ozdemir</surname><given-names>O</given-names></name>
<name><surname>Altintas</surname><given-names>O</given-names></name>
<name><surname>Altintas</surname><given-names>L</given-names></name>
<name><surname>Yildiz</surname><given-names>DK</given-names></name>
<name><surname>Sener</surname><given-names>E</given-names></name>
<name><surname>Caglar</surname><given-names>Y</given-names></name></person-group><article-title>Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization</article-title><source>Can J Ophthalmol</source><year>2013</year><volume>48</volume><fpage>115</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">23561605</pub-id>
</element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoo</surname><given-names>AR</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2014</year><volume>33</volume><fpage>1088</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">25119962</pub-id>
</element-citation></ref><ref id="R36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Onder</surname><given-names>HI</given-names></name>
<name><surname>Erdurmus</surname><given-names>M</given-names></name>
<name><surname>Bucak</surname><given-names>YY</given-names></name>
<name><surname>Simavli</surname><given-names>H</given-names></name>
<name><surname>Oktay</surname><given-names>M</given-names></name>
<name><surname>Kukner</surname><given-names>AS</given-names></name></person-group><article-title>Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization</article-title><source>Int J Ophthalmol</source><year>2014</year><volume>7</volume><fpage>220</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24790861</pub-id>
</element-citation></ref><ref id="R37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hashemian</surname><given-names>MN</given-names></name>
<name><surname>Mahrjerdi</surname><given-names>HZ</given-names></name>
<name><surname>Mazloumi</surname><given-names>M</given-names></name>
<name><surname>Safizadeh</surname><given-names>MS</given-names></name>
<name><surname>Shakiba</surname><given-names>Y</given-names></name>
<name><surname>Rahimi</surname><given-names>F</given-names></name>
<etal/></person-group><article-title>Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats</article-title><source>J Res Med Sci</source><year>2017</year><volume>22</volume><fpage>16</fpage><pub-id pub-id-type="pmid">28458707</pub-id>
</element-citation></ref><ref id="R38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sener</surname><given-names>E</given-names></name>
<name><surname>Yuksel</surname><given-names>N</given-names></name>
<name><surname>Yildiz</surname><given-names>DK</given-names></name>
<name><surname>Yilmaz</surname><given-names>B</given-names></name>
<name><surname>Ozdemir</surname><given-names>O</given-names></name>
<name><surname>Caglar</surname><given-names>Y</given-names></name>
<etal/></person-group><article-title>The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model</article-title><source>Curr Eye Res</source><year>2011</year><volume>36</volume><fpage>1005</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">21999227</pub-id>
</element-citation></ref><ref id="R39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akar</surname><given-names>EE</given-names></name>
<name><surname>Oner</surname><given-names>V</given-names></name>
<name><surname>K&#x000fc;&#x000e7;&#x000fc;kerd&#x000f6;nmez</surname><given-names>C</given-names></name>
<name><surname>Ayd&#x00131;n Akova</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model</article-title><source>Int J Ophthalmol</source><year>2013</year><volume>6</volume><fpage>136</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">23638411</pub-id>
</element-citation></ref><ref id="R40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>YR</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>Inhibitory effect of topical aflibercept on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2015</year><volume>34</volume><fpage>1303</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">26114826</pub-id>
</element-citation></ref><ref id="R41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ucgul</surname><given-names>RK</given-names></name>
<name><surname>Celebi</surname><given-names>S</given-names></name>
<name><surname>Yilmaz</surname><given-names>NS</given-names></name>
<name><surname>Bukan</surname><given-names>N</given-names></name>
<name><surname>Ucgul</surname><given-names>AY</given-names></name></person-group><article-title>Intrastromal versus subconjunctival anti- VEGF agents for treatment of corneal neovascularization: A rabbit study</article-title><source>Eye (Lond)</source><year>2021</year><volume>35</volume><fpage>3123</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">33469129</pub-id>
</element-citation></ref><ref id="R42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dastjerdi</surname><given-names>MH</given-names></name>
<name><surname>Sadrai</surname><given-names>Z</given-names></name>
<name><surname>Saban</surname><given-names>DR</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<name><surname>Dana</surname><given-names>R</given-names></name></person-group><article-title>Corneal penetration of topical and subconjunctival bevacizumab</article-title><source>Invest Ophthalmol Vis Sci</source><year>2011</year><volume>52</volume><fpage>8718</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">22003112</pub-id>
</element-citation></ref><ref id="R43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manzano</surname><given-names>RP</given-names></name>
<name><surname>Peyman</surname><given-names>GA</given-names></name>
<name><surname>Khan</surname><given-names>P</given-names></name>
<name><surname>Carvounis</surname><given-names>PE</given-names></name>
<name><surname>Kivilcim</surname><given-names>M</given-names></name>
<name><surname>Ren</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)</article-title><source>Br J Ophthalmol</source><year>2007</year><volume>91</volume><fpage>804</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17179168</pub-id>
</element-citation></ref><ref id="R44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>SF</given-names></name>
<name><surname>Dastjerdi</surname><given-names>MH</given-names></name>
<name><surname>Ferrari</surname><given-names>G</given-names></name>
<name><surname>Okanobo</surname><given-names>A</given-names></name>
<name><surname>Bower</surname><given-names>KS</given-names></name>
<name><surname>Ryan</surname><given-names>DS</given-names></name>
<etal/></person-group><article-title>Short-term topical bevacizumab in the treatment of stable corneal neovascularization</article-title><source>Am J Ophthalmol</source><year>2012</year><volume>154</volume><fpage>940</fpage><lpage>8.e1</lpage><pub-id pub-id-type="pmid">22967868</pub-id>
</element-citation></ref><ref id="R45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>SW</given-names></name>
<name><surname>Ha</surname><given-names>BJ</given-names></name>
<name><surname>Kim</surname><given-names>EK</given-names></name>
<name><surname>Tchah</surname><given-names>H</given-names></name>
<name><surname>Kim</surname><given-names>TI</given-names></name></person-group><article-title>The effect of topical bevacizumab on corneal neovascularization</article-title><source>Ophthalmology</source><year>2008</year><volume>115</volume><fpage>e33</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18439681</pub-id>
</element-citation></ref><ref id="R46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koenig</surname><given-names>Y</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Horn</surname><given-names>F</given-names></name>
<name><surname>Kruse</surname><given-names>F</given-names></name>
<name><surname>Straub</surname><given-names>K</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2009</year><volume>247</volume><fpage>1375</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">19415316</pub-id>
</element-citation></ref><ref id="R47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bahar</surname><given-names>I</given-names></name>
<name><surname>Kaiserman</surname><given-names>I</given-names></name>
<name><surname>McAllum</surname><given-names>P</given-names></name>
<name><surname>Rootman</surname><given-names>D</given-names></name>
<name><surname>Slomovic</surname><given-names>A</given-names></name></person-group><article-title>Subconjunctival bevacizumab injection for corneal neovascularization</article-title><source>Cornea</source><year>2008</year><volume>27</volume><fpage>142</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18216566</pub-id>
</element-citation></ref><ref id="R48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Papathanassiou</surname><given-names>M</given-names></name>
<name><surname>Theodoropoulou</surname><given-names>S</given-names></name>
<name><surname>Analitis</surname><given-names>A</given-names></name>
<name><surname>Tzonou</surname><given-names>A</given-names></name>
<name><surname>Theodossiadis</surname><given-names>PG</given-names></name></person-group><article-title>Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: A meta-analysis</article-title><source>Cornea</source><year>2013</year><volume>32</volume><fpage>435</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22668582</pub-id>
</element-citation></ref><ref id="R49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrari</surname><given-names>G</given-names></name>
<name><surname>Dastjerdi</surname><given-names>MH</given-names></name>
<name><surname>Okanobo</surname><given-names>A</given-names></name>
<name><surname>Cheng</surname><given-names>SF</given-names></name>
<name><surname>Amparo</surname><given-names>F</given-names></name>
<name><surname>Nallasamy</surname><given-names>N</given-names></name>
<etal/></person-group><article-title>Topical ranibizumab as a treatment of corneal neovascularization</article-title><source>Cornea</source><year>2013</year><volume>32</volume><fpage>992</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23407316</pub-id>
</element-citation></ref><ref id="R50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stevenson</surname><given-names>W</given-names></name>
<name><surname>Cheng</surname><given-names>SF</given-names></name>
<name><surname>Dastjerdi</surname><given-names>MH</given-names></name>
<name><surname>Ferrari</surname><given-names>G</given-names></name>
<name><surname>Dana</surname><given-names>R</given-names></name></person-group><article-title>Corneal neovascularization and the utility of topical VEGF inhibition: Ranibizumab (Lucentis) vs bevacizumab (Avastin)</article-title><source>Ocul Surf</source><year>2012</year><volume>10</volume><fpage>67</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">22482468</pub-id>
</element-citation></ref><ref id="R51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liarakos</surname><given-names>VS</given-names></name>
<name><surname>Papaconstantinou</surname><given-names>D</given-names></name>
<name><surname>Vergados</surname><given-names>I</given-names></name>
<name><surname>Douvali</surname><given-names>M</given-names></name>
<name><surname>Theodossiadis</surname><given-names>PG</given-names></name></person-group><article-title>The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: Study on an animal model</article-title><source>Eur J Ophthalmol</source><year>2014</year><volume>24</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">24242219</pub-id>
</element-citation></ref><ref id="R52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JH</given-names></name>
<name><surname>Seo</surname><given-names>HW</given-names></name>
<name><surname>Han</surname><given-names>HC</given-names></name>
<name><surname>Lee</surname><given-names>JH</given-names></name>
<name><surname>Choi</surname><given-names>SK</given-names></name>
<name><surname>Lee</surname><given-names>D</given-names></name></person-group><article-title>The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: A preliminary study</article-title><source>Korean J Ophthalmol</source><year>2013</year><volume>27</volume><fpage>235</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">23908568</pub-id>
</element-citation></ref><ref id="R53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrade</surname><given-names>N</given-names></name>
<name><surname>Crispim Ribeiro</surname><given-names>J</given-names></name>
<name><surname>Ara&#x000fa;jo</surname><given-names>ESPM</given-names></name>
<name><surname>Savio</surname><given-names>D</given-names></name>
<name><surname>Fechine</surname><given-names>FV</given-names></name>
<name><surname>de Moraes</surname><given-names>MO</given-names></name></person-group><article-title>Effect of topical instillation of pegaptanib sodium upon inflammatory corneal neovascularization in rabbits</article-title><source>J Ocul Pharmacol Ther</source><year>2021</year><volume>37</volume><fpage>277</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">33891495</pub-id>
</element-citation></ref><ref id="R54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Oliveira Dias</surname><given-names>JR</given-names></name>
<name><surname>de Andrade</surname><given-names>GC</given-names></name>
<name><surname>Novais</surname><given-names>EA</given-names></name>
<name><surname>Farah</surname><given-names>ME</given-names></name>
<name><surname>Rodrigues</surname><given-names>EB</given-names></name></person-group><article-title>Fusion proteins for treatment of retinal diseases: Aflibercept, ziv-aflibercept, and conbercept</article-title><source>Int J Retina Vitreous</source><year>2016</year><volume>2</volume><fpage>3</fpage><pub-id pub-id-type="pmid">27847621</pub-id>
</element-citation></ref><ref id="R55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>S</given-names></name>
<name><surname>Yang</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>The efficacy and safety of aflibercept and conbercept in diabetic macular edema</article-title><source>Drug Des Devel Ther</source><year>2018</year><volume>12</volume><fpage>3471</fpage><lpage>83</lpage></element-citation></ref><ref id="R56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eski</surname><given-names>MT</given-names></name>
<name><surname>Teberik</surname><given-names>K</given-names></name>
<name><surname>Oltulu</surname><given-names>P</given-names></name>
<name><surname>Ankaral&#x00131;</surname><given-names>H</given-names></name>
<name><surname>Kaya</surname><given-names>M</given-names></name>
<name><surname>Alpay</surname><given-names>M</given-names></name></person-group><article-title>The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization</article-title><source>Hum Exp Toxicol</source><year>2022</year><volume>41</volume><fpage>9603271221084674</fpage><pub-id pub-id-type="pmid">35465742</pub-id>
</element-citation></ref><ref id="R57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sella</surname><given-names>R</given-names></name>
<name><surname>Gal-Or</surname><given-names>O</given-names></name>
<name><surname>Livny</surname><given-names>E</given-names></name>
<name><surname>Dachbash</surname><given-names>M</given-names></name>
<name><surname>Nisgav</surname><given-names>Y</given-names></name>
<name><surname>Weinberger</surname><given-names>D</given-names></name>
<etal/></person-group><article-title>Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model</article-title><source>Exp Eye Res</source><year>2016</year><volume>146</volume><fpage>224</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">27020759</pub-id>
</element-citation></ref><ref id="R58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sella</surname><given-names>R</given-names></name>
<name><surname>Ben Ishai</surname><given-names>M</given-names></name>
<name><surname>Livny</surname><given-names>E</given-names></name>
<name><surname>Nahum</surname><given-names>Y</given-names></name>
<name><surname>Bahar</surname><given-names>I</given-names></name></person-group><article-title>Subconjunctival aflibercept for the treatment of formed corneal neovascularization</article-title><source>Eye Contact Lens</source><year>2021</year><volume>47</volume><fpage>180</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">32443011</pub-id>
</element-citation></ref><ref id="R59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarah</surname><given-names>B</given-names></name>
<name><surname>Ibtissam</surname><given-names>H</given-names></name>
<name><surname>Mohammed</surname><given-names>B</given-names></name>
<name><surname>Hasna</surname><given-names>S</given-names></name>
<name><surname>Abdeljalil</surname><given-names>M</given-names></name></person-group><article-title>Intrastromal injection of bevacizumab in the management of corneal neovascularization: About 25 eyes</article-title><source>J Ophthalmol</source><year>2016</year><volume>2016</volume><fpage>6084270</fpage><pub-id pub-id-type="pmid">27610242</pub-id>
</element-citation></ref><ref id="R60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yeung</surname><given-names>SN</given-names></name>
<name><surname>Lichtinger</surname><given-names>A</given-names></name>
<name><surname>Kim</surname><given-names>P</given-names></name>
<name><surname>Amiran</surname><given-names>MD</given-names></name>
<name><surname>Slomovic</surname><given-names>AR</given-names></name></person-group><article-title>Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization</article-title><source>Cornea</source><year>2011</year><volume>30</volume><fpage>1110</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">21673570</pub-id>
</element-citation></ref><ref id="R61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>YC</given-names></name>
<name><surname>Grossniklaus</surname><given-names>HE</given-names></name>
<name><surname>Edelhauser</surname><given-names>HF</given-names></name>
<name><surname>Prausnitz</surname><given-names>MR</given-names></name></person-group><article-title>Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization</article-title><source>Invest Ophthalmol Vis Sci</source><year>2014</year><volume>55</volume><fpage>7376</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">25212779</pub-id>
</element-citation></ref><ref id="R62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>AA</given-names></name>
<name><surname>Mammo</surname><given-names>DA</given-names></name>
<name><surname>Page</surname><given-names>MA</given-names></name></person-group><article-title>Intrastromal bevacizumab in the management of corneal neovascularization: A retrospective review</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2020</year><volume>258</volume><fpage>167</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">31713747</pub-id>
</element-citation></ref><ref id="R63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bodnar</surname><given-names>RJ</given-names></name></person-group><article-title>Anti-angiogenic drugs: Involvement in cutaneous side effects and wound-healing complication</article-title><source>Adv Wound Care (New Rochelle)</source><year>2014</year><volume>3</volume><fpage>635</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">25302138</pub-id>
</element-citation></ref><ref id="R64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Onderka</surname><given-names>J</given-names></name>
<name><surname>Rummelt</surname><given-names>C</given-names></name>
<name><surname>Dietrich</surname><given-names>T</given-names></name>
<name><surname>Bachmann</surname><given-names>B</given-names></name>
<name><surname>Kruse</surname><given-names>FE</given-names></name>
<etal/></person-group><article-title>Safety profile of topical VEGF neutralization at the cornea</article-title><source>Invest Ophthalmol Vis Sci</source><year>2009</year><volume>50</volume><fpage>2095</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">19151400</pub-id>
</element-citation></ref><ref id="R65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>JY</given-names></name>
<name><surname>Kim</surname><given-names>MK</given-names></name>
<name><surname>Wee</surname><given-names>WR</given-names></name></person-group><article-title>Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy</article-title><source>Cornea</source><year>2009</year><volume>28</volume><fpage>1070</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">19724199</pub-id>
</element-citation></ref><ref id="R66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>P&#x000e9;rez-Santonja</surname><given-names>JJ</given-names></name>
<name><surname>Campos-Mollo</surname><given-names>E</given-names></name>
<name><surname>Lled&#x000f3;-Riquelme</surname><given-names>M</given-names></name>
<name><surname>Javaloy</surname><given-names>J</given-names></name>
<name><surname>Ali&#x000f3;</surname><given-names>JL</given-names></name></person-group><article-title>Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model</article-title><source>Am J Ophthalmol</source><year>2010</year><volume>150</volume><fpage>519</fpage><lpage>28.e1</lpage><pub-id pub-id-type="pmid">20591397</pub-id>
</element-citation></ref><ref id="R67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>You</surname><given-names>IC</given-names></name>
<name><surname>Kang</surname><given-names>IS</given-names></name>
<name><surname>Lee</surname><given-names>SH</given-names></name>
<name><surname>Yoon</surname><given-names>KC</given-names></name></person-group><article-title>Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization</article-title><source>Acta Ophthalmol</source><year>2009</year><volume>87</volume><fpage>653</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19021596</pub-id>
</element-citation></ref><ref id="R68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benayoun</surname><given-names>Y</given-names></name>
<name><surname>Adenis</surname><given-names>JP</given-names></name>
<name><surname>Casse</surname><given-names>G</given-names></name>
<name><surname>Forte</surname><given-names>R</given-names></name>
<name><surname>Robert</surname><given-names>PY</given-names></name></person-group><article-title>Effects of subconjunctival bevacizumab on corneal neovascularization: Results of a prospective study</article-title><source>Cornea</source><year>2012</year><volume>31</volume><fpage>937</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22357391</pub-id>
</element-citation></ref><ref id="R69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>HS</given-names></name>
<name><surname>Chen</surname><given-names>TC</given-names></name>
<name><surname>Hu</surname><given-names>FR</given-names></name>
<name><surname>Chen</surname><given-names>WL</given-names></name></person-group><article-title>Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab</article-title><source>Cornea</source><year>2013</year><volume>32</volume><fpage>1446</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">24055900</pub-id>
</element-citation></ref><ref id="R70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Britton</surname><given-names>AK</given-names></name>
<name><surname>Crayford</surname><given-names>BB</given-names></name></person-group><article-title>Resolution of refractory corneal neovascularization with subconjunctival bevacizumab</article-title><source>Case Rep Ophthalmol</source><year>2020</year><volume>11</volume><fpage>652</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">33442379</pub-id>
</element-citation></ref><ref id="R71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cavallini</surname><given-names>GM</given-names></name>
<name><surname>Pellegrini</surname><given-names>G</given-names></name>
<name><surname>Volante</surname><given-names>V</given-names></name>
<name><surname>Ducange</surname><given-names>P</given-names></name>
<name><surname>De Maria</surname><given-names>M</given-names></name>
<name><surname>Torlai</surname><given-names>G</given-names></name>
<etal/></person-group><article-title>Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab</article-title><source>Clin Ophthalmol</source><year>2014</year><volume>8</volume><fpage>1671</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">25210437</pub-id>
</element-citation></ref><ref id="R72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iannetti</surname><given-names>L</given-names></name>
<name><surname>Abbouda</surname><given-names>A</given-names></name>
<name><surname>Fabiani</surname><given-names>C</given-names></name>
<name><surname>Zito</surname><given-names>R</given-names></name>
<name><surname>Campanella</surname><given-names>M</given-names></name></person-group><article-title>Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: A case report</article-title><source>J Med Case Rep</source><year>2013</year><volume>7</volume><fpage>199</fpage><pub-id pub-id-type="pmid">23889894</pub-id>
</element-citation></ref><ref id="R73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krasnick</surname><given-names>NM</given-names></name>
<name><surname>Spigelman</surname><given-names>AV</given-names></name></person-group><article-title>Comparison of yellow dye, continuous wave Nd:YAG, and argon green laser on experimentally induced corneal neovascularization</article-title><source>J Refract Surg</source><year>1995</year><volume>11</volume><fpage>45</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7641049</pub-id>
</element-citation></ref><ref id="R74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>AJ</given-names></name>
<name><surname>Watson</surname><given-names>BD</given-names></name>
<name><surname>Hernandez</surname><given-names>E</given-names></name>
<name><surname>Tseng</surname><given-names>SC</given-names></name></person-group><article-title>Photothrombosis of corneal neovascularization by intravenous rose bengal and argon laser irradiation</article-title><source>Arch Ophthalmol</source><year>1988</year><volume>106</volume><fpage>680</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2451909</pub-id>
</element-citation></ref><ref id="R75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nirankari</surname><given-names>VS</given-names></name>
<name><surname>Dandona</surname><given-names>L</given-names></name>
<name><surname>Rodrigues</surname><given-names>MM</given-names></name></person-group><article-title>Laser photocoagulation of experimental corneal stromal vascularization. Efficacy and histopathology</article-title><source>Ophthalmology</source><year>1993</year><volume>100</volume><fpage>111</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8433815</pub-id>
</element-citation></ref><ref id="R76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>A</given-names></name>
<name><surname>Samal</surname><given-names>A</given-names></name>
<name><surname>Narang</surname><given-names>S</given-names></name>
<name><surname>Gutpa</surname><given-names>A</given-names></name>
<name><surname>Ram</surname><given-names>J</given-names></name>
<name><surname>Gupta</surname><given-names>A</given-names></name></person-group><article-title>Frequency doubled Nd:YAG (532 nm) laser photocoagulation in corneal vascularisation: Efficacy and time sequenced changes</article-title><source>Indian J Ophthalmol</source><year>2001</year><volume>49</volume><fpage>235</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12930115</pub-id>
</element-citation></ref><ref id="R77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>J</given-names></name>
<name><surname>Gehra</surname><given-names>A</given-names></name>
<name><surname>Sirohi</surname><given-names>N</given-names></name></person-group><article-title>Role of frequency doubled Nd: Yag Laser in treatment of corneal neovascularisation</article-title><source>J Clin Diagn Res</source><year>2016</year><volume>10</volume><fpage>Nc01</fpage><lpage>4</lpage></element-citation></ref><ref id="R78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>Y</given-names></name>
<name><surname>Le</surname><given-names>VNH</given-names></name>
<name><surname>Clahsen</surname><given-names>T</given-names></name>
<name><surname>Schneider</surname><given-names>AC</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Photodynamic therapy leads to time-dependent regression of pathologic corneal (Lymph) angiogenesis and promotes high-risk corneal allograft survival</article-title><source>Invest Ophthalmol Vis Sci</source><year>2017</year><volume>58</volume><fpage>5862</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">29145577</pub-id>
</element-citation></ref><ref id="R79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bucher</surname><given-names>F</given-names></name>
<name><surname>Bi</surname><given-names>Y</given-names></name>
<name><surname>Gehlsen</surname><given-names>U</given-names></name>
<name><surname>Hos</surname><given-names>D</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name></person-group><article-title>Regression of mature lymphatic vessels in the cornea by photodynamic therapy</article-title><source>Br J Ophthalmol</source><year>2014</year><volume>98</volume><fpage>391</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24414403</pub-id>
</element-citation></ref><ref id="R80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pillai</surname><given-names>CT</given-names></name>
<name><surname>Dua</surname><given-names>HS</given-names></name>
<name><surname>Hossain</surname><given-names>P</given-names></name></person-group><article-title>Fine needle diathermy occlusion of corneal vessels</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>2148</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10892856</pub-id>
</element-citation></ref><ref id="R81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faraj</surname><given-names>LA</given-names></name>
<name><surname>Elalfy</surname><given-names>MS</given-names></name>
<name><surname>Said</surname><given-names>DG</given-names></name>
<name><surname>Dua</surname><given-names>HS</given-names></name></person-group><article-title>Fine needle diathermy occlusion of corneal vessels</article-title><source>Br J Ophthalmol</source><year>2014</year><volume>98</volume><fpage>1287</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">24782468</pub-id>
</element-citation></ref><ref id="R82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>VNH</given-names></name>
<name><surname>Hou</surname><given-names>Y</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Supplemental Anti Vegf A-therapy prevents rebound neovascularisation after fine needle diathermy treatment to regress pathological corneal (LYMPH) angiogenesis</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>3908</fpage><pub-id pub-id-type="pmid">32127563</pub-id>
</element-citation></ref><ref id="R83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hos</surname><given-names>D</given-names></name>
<name><surname>Le</surname><given-names>VNH</given-names></name>
<name><surname>Hellmich</surname><given-names>M</given-names></name>
<name><surname>Siebelmann</surname><given-names>S</given-names></name>
<name><surname>Roters</surname><given-names>S</given-names></name>
<name><surname>Bachmann</surname><given-names>BO</given-names></name>
<etal/></person-group><article-title>Risk of corneal graft rejection after high-risk keratoplasty following fine-needle vessel coagulation of corneal neovascularization combined with bevacizumab: A pilot study</article-title><source>Transplant Direct</source><year>2019</year><volume>5</volume><fpage>e452</fpage><pub-id pub-id-type="pmid">31165087</pub-id>
</element-citation></ref><ref id="R84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elbaz</surname><given-names>U</given-names></name>
<name><surname>Mireskandari</surname><given-names>K</given-names></name>
<name><surname>Shen</surname><given-names>C</given-names></name>
<name><surname>Ali</surname><given-names>A</given-names></name></person-group><article-title>Corneal fine needle diathermy with adjuvant bevacizumab to treat corneal neovascularization in children</article-title><source>Cornea</source><year>2015</year><volume>34</volume><fpage>773</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25811720</pub-id>
</element-citation></ref><ref id="R85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>VNH</given-names></name>
<name><surname>Schneider</surname><given-names>AC</given-names></name>
<name><surname>Scholz</surname><given-names>R</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Fine needle-diathermy regresses pathological corneal (Lymph) angiogenesis and promotes high-risk corneal transplant survival</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>5707</fpage><pub-id pub-id-type="pmid">29632336</pub-id>
</element-citation></ref><ref id="R86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cursiefen</surname><given-names>C</given-names></name>
<name><surname>Hofmann-Rummelt</surname><given-names>C</given-names></name>
<name><surname>K&#x000fc;chle</surname><given-names>M</given-names></name>
<name><surname>Schl&#x000f6;tzer-Schrehardt</surname><given-names>U</given-names></name></person-group><article-title>Pericyte recruitment in human corneal angiogenesis: An ultrastructural study with clinicopathological correlation</article-title><source>Br J Ophthalmol</source><year>2003</year><volume>87</volume><fpage>101</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12488272</pub-id>
</element-citation></ref><ref id="R87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spiteri</surname><given-names>N</given-names></name>
<name><surname>Romano</surname><given-names>V</given-names></name>
<name><surname>Zheng</surname><given-names>Y</given-names></name>
<name><surname>Yadav</surname><given-names>S</given-names></name>
<name><surname>Dwivedi</surname><given-names>R</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Corneal angiography for guiding and evaluating fine-needle diathermy treatment of corneal neovascularization</article-title><source>Ophthalmology</source><year>2015</year><volume>122</volume><fpage>1079</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">25841974</pub-id>
</element-citation></ref><ref id="R88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>BY</given-names></name>
<name><surname>Riaz</surname><given-names>KM</given-names></name>
<name><surname>Bakhtiari</surname><given-names>P</given-names></name>
<name><surname>Chan</surname><given-names>CC</given-names></name>
<name><surname>Welder</surname><given-names>JD</given-names></name>
<name><surname>Holland</surname><given-names>EJ</given-names></name>
<etal/></person-group><article-title>Medically reversible limbal stem cell disease: Clinical features and management strategies</article-title><source>Ophthalmology</source><year>2014</year><volume>121</volume><fpage>2053</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24908203</pub-id>
</element-citation></ref><ref id="R89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>Q</given-names></name>
<name><surname>Chauhan</surname><given-names>T</given-names></name>
<name><surname>Yung</surname><given-names>M</given-names></name>
<name><surname>Tseng</surname><given-names>CH</given-names></name>
<name><surname>Deng</surname><given-names>SX</given-names></name></person-group><article-title>Outcomes of limbal stem cell transplant: A meta-analysis</article-title><source>JAMA Ophthalmol</source><year>2020</year><volume>138</volume><fpage>660</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">32324211</pub-id>
</element-citation></ref><ref id="R90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sangwan</surname><given-names>VS</given-names></name>
<name><surname>Basu</surname><given-names>S</given-names></name>
<name><surname>MacNeil</surname><given-names>S</given-names></name>
<name><surname>Balasubramanian</surname><given-names>D</given-names></name></person-group><article-title>Simple limbal epithelial transplantation (SLET): A novel surgical technique for the treatment of unilateral limbal stem cell deficiency</article-title><source>Br J Ophthalmol</source><year>2012</year><volume>96</volume><fpage>931</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">22328817</pub-id>
</element-citation></ref><ref id="R91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jackson</surname><given-names>CJ</given-names></name>
<name><surname>Myklebust Ern&#x000f8;</surname><given-names>IT</given-names></name>
<name><surname>Ringstad</surname><given-names>H</given-names></name>
<name><surname>T&#x000f8;nseth</surname><given-names>KA</given-names></name>
<name><surname>Dartt</surname><given-names>DA</given-names></name>
<name><surname>Utheim</surname><given-names>TP</given-names></name></person-group><article-title>Simple limbal epithelial transplantation: Current status and future perspectives</article-title><source>Stem Cells Transl Med</source><year>2020</year><volume>9</volume><fpage>316</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">31802651</pub-id>
</element-citation></ref><ref id="R92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seki</surname><given-names>Y</given-names></name>
<name><surname>Toba</surname><given-names>K</given-names></name>
<name><surname>Fuse</surname><given-names>I</given-names></name>
<name><surname>Sato</surname><given-names>N</given-names></name>
<name><surname>Niwano</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells</article-title><source>Thromb Res</source><year>2005</year><volume>115</volume><fpage>219</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">15617745</pub-id>
</element-citation></ref><ref id="R93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mimouni</surname><given-names>M</given-names></name>
<name><surname>Ouano</surname><given-names>D</given-names></name></person-group><article-title>Initial outcomes of mitomycin intravascular chemoembolization (MICE) for corneal neovascularization</article-title><source>Int Ophthalmol</source><year>2022</year><volume>42</volume><fpage>2407</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">35099664</pub-id>
</element-citation></ref><ref id="R94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Addeen</surname><given-names>SZ</given-names></name>
<name><surname>Oyoun</surname><given-names>Z</given-names></name>
<name><surname>Alfhaily</surname><given-names>H</given-names></name>
<name><surname>Anbari</surname><given-names>A</given-names></name></person-group><article-title>Outcomes of mitomycin C intravascular chemoembolization (MICE) in refractory corneal neovascularization after failed keratoplasty</article-title><source>Digit J Ophthalmol</source><year>2023</year><volume>29</volume><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">37101562</pub-id>
</element-citation></ref><ref id="R95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>D</given-names></name>
<name><surname>Lim</surname><given-names>DK</given-names></name>
<name><surname>Lim</surname><given-names>BXH</given-names></name>
<name><surname>Wong</surname><given-names>N</given-names></name>
<name><surname>Hafezi</surname><given-names>F</given-names></name>
<name><surname>Manotosh</surname><given-names>R</given-names></name>
<etal/></person-group><article-title>Corneal cross-linking: The evolution of treatment for corneal diseases</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>686630</fpage><pub-id pub-id-type="pmid">34349648</pub-id>
</element-citation></ref><ref id="R96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
<name><surname>Reinach</surname><given-names>PS</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Ge</surname><given-names>C</given-names></name>
<name><surname>Qu</surname><given-names>J</given-names></name>
<etal/></person-group><article-title>Corneal collagen cross-linking with Riboflavin and UVA regulates hemangiogenesis and lymphangiogenesis in rats</article-title><source>Invest Ophthalmol Vis Sci</source><year>2018</year><volume>59</volume><fpage>3702</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">30029257</pub-id>
</element-citation></ref><ref id="R97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertollo</surname><given-names>CM</given-names></name>
<name><surname>Oliveira</surname><given-names>AC</given-names></name>
<name><surname>Rocha</surname><given-names>LT</given-names></name>
<name><surname>Costa</surname><given-names>KA</given-names></name>
<name><surname>Nascimento</surname><given-names>EB</given-names><suffix>Jr</suffix></name>
<name><surname>Coelho</surname><given-names>MM</given-names></name></person-group><article-title>Characterization of the antinociceptive and anti-inflammatory activities of riboflavin in different experimental models</article-title><source>Eur J Pharmacol</source><year>2006</year><volume>547</volume><fpage>184</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16962092</pub-id>
</element-citation></ref><ref id="R98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Notara</surname><given-names>M</given-names></name>
<name><surname>Refaian</surname><given-names>N</given-names></name>
<name><surname>Braun</surname><given-names>G</given-names></name>
<name><surname>Steven</surname><given-names>P</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Short-term ultraviolet A irradiation leads to dysfunction of the limbal niche cells and an antilymphangiogenic and anti- inflammatory micromilieu</article-title><source>Invest Ophthalmol Vis Sci</source><year>2016</year><volume>57</volume><fpage>928</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">26943156</pub-id>
</element-citation></ref><ref id="R99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>Y</given-names></name>
<name><surname>Le</surname><given-names>VNH</given-names></name>
<name><surname>T&#x000f3;th</surname><given-names>G</given-names></name>
<name><surname>Siebelmann</surname><given-names>S</given-names></name>
<name><surname>Horstmann</surname><given-names>J</given-names></name>
<name><surname>Gabriel</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>UV light crosslinking regresses mature corneal blood and lymphatic vessels and promotes subsequent high-risk corneal transplant survival</article-title><source>Am J Transplant</source><year>2018</year><volume>18</volume><fpage>2873</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">29673063</pub-id>
</element-citation></ref><ref id="R100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>T</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Effect of collagen cross-linking on alkali burn-induced corneal neovascularization in rabbits</article-title><source>J Ophthalmol</source><year>2018</year><volume>2018</volume><fpage>7325483</fpage><pub-id pub-id-type="pmid">30402279</pub-id>
</element-citation></ref><ref id="R101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kesim</surname><given-names>E</given-names></name>
<name><surname>Pirhan</surname><given-names>D</given-names></name>
<name><surname>Yardimoglu Yilmaz</surname><given-names>M</given-names></name>
<name><surname>Yuksel</surname><given-names>N</given-names></name>
<name><surname>Yazir</surname><given-names>Y</given-names></name>
<name><surname>Bicaklioglu</surname><given-names>G</given-names></name>
<etal/></person-group><article-title>Comparative analysis of matrix-regenerating agent and corneal cross-linking in an experimental alkali burn rabbit model</article-title><source>Curr Eye Res</source><year>2022</year><volume>47</volume><fpage>187</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">34435926</pub-id>
</element-citation></ref><ref id="R102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Subasi</surname><given-names>S</given-names></name>
<name><surname>Altintas</surname><given-names>O</given-names></name>
<name><surname>Yardimoglu</surname><given-names>M</given-names></name>
<name><surname>Yazir</surname><given-names>Y</given-names></name>
<name><surname>Karaman</surname><given-names>S</given-names></name>
<name><surname>Rencber</surname><given-names>SF</given-names></name>
<etal/></person-group><article-title>Comparison of collagen cross-linking and amniotic membrane transplantation in an experimental alkali burn rabbit model</article-title><source>Cornea</source><year>2017</year><volume>36</volume><fpage>1106</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">28704317</pub-id>
</element-citation></ref><ref id="R103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colombo-Barboza</surname><given-names>M</given-names></name>
<name><surname>Colombo-Barboza</surname><given-names>G</given-names></name>
<name><surname>Felberg</surname><given-names>S</given-names></name>
<name><surname>Dantas</surname><given-names>PE</given-names></name>
<name><surname>Sato</surname><given-names>EH</given-names></name></person-group><article-title>Induction of corneal collagen cross-linking in experimental corneal alkali burns in rabbits</article-title><source>Arq Bras Oftalmol</source><year>2014</year><volume>77</volume><fpage>310</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">25494378</pub-id>
</element-citation></ref><ref id="R104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schaub</surname><given-names>F</given-names></name>
<name><surname>Hou</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Hos</surname><given-names>D</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Corneal crosslinking to regress pathologic corneal neovascularization before high-risk keratoplasty</article-title><source>Cornea</source><year>2021</year><volume>40</volume><fpage>147</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">33395116</pub-id>
</element-citation></ref><ref id="R105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anguela</surname><given-names>XM</given-names></name>
<name><surname>High</surname><given-names>KA</given-names></name></person-group><article-title>Entering the modern era of gene therapy</article-title><source>Annu Rev Med</source><year>2019</year><volume>70</volume><fpage>273</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">30477394</pub-id>
</element-citation></ref><ref id="R106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amador</surname><given-names>C</given-names></name>
<name><surname>Shah</surname><given-names>R</given-names></name>
<name><surname>Ghiam</surname><given-names>S</given-names></name>
<name><surname>Kramerov</surname><given-names>AA</given-names></name>
<name><surname>Ljubimov</surname><given-names>AV</given-names></name></person-group><article-title>Gene therapy in the anterior eye segment</article-title><source>Curr Gene Ther</source><year>2022</year><volume>22</volume><fpage>104</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">33902406</pub-id>
</element-citation></ref><ref id="R107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai</surname><given-names>YK</given-names></name>
<name><surname>Shen</surname><given-names>WY</given-names></name>
<name><surname>Brankov</surname><given-names>M</given-names></name>
<name><surname>Lai</surname><given-names>CM</given-names></name>
<name><surname>Constable</surname><given-names>IJ</given-names></name>
<name><surname>Rakoczy</surname><given-names>PE</given-names></name></person-group><article-title>Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy</article-title><source>Gene Ther</source><year>2002</year><volume>9</volume><fpage>804</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12040462</pub-id>
</element-citation></ref><ref id="R108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iriyama</surname><given-names>A</given-names></name>
<name><surname>Usui</surname><given-names>T</given-names></name>
<name><surname>Yanagi</surname><given-names>Y</given-names></name>
<name><surname>Amano</surname><given-names>S</given-names></name>
<name><surname>Oba</surname><given-names>M</given-names></name>
<name><surname>Miyata</surname><given-names>K</given-names></name>
<etal/></person-group><article-title>Gene transfer using micellar nanovectors inhibits corneal neovascularization in vivo</article-title><source>Cornea</source><year>2011</year><volume>30</volume><fpage>1423</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21975440</pub-id>
</element-citation></ref><ref id="R109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>H</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Tian</surname><given-names>Y</given-names></name>
<etal/></person-group><article-title>Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression</article-title><source>Biochem Biophys Res Commun</source><year>2007</year><volume>361</volume><fpage>946</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17692288</pub-id>
</element-citation></ref><ref id="R110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>KC</given-names></name>
<name><surname>Bae</surname><given-names>JA</given-names></name>
<name><surname>Park</surname><given-names>HJ</given-names></name>
<name><surname>Im</surname><given-names>SK</given-names></name>
<name><surname>Oh</surname><given-names>HJ</given-names></name>
<name><surname>Lin</surname><given-names>XH</given-names></name>
<etal/></person-group><article-title>Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model</article-title><source>Gene Ther</source><year>2009</year><volume>16</volume><fpage>973</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">19421232</pub-id>
</element-citation></ref><ref id="R111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai</surname><given-names>CM</given-names></name>
<name><surname>Spilsbury</surname><given-names>K</given-names></name>
<name><surname>Brankov</surname><given-names>M</given-names></name>
<name><surname>Zaknich</surname><given-names>T</given-names></name>
<name><surname>Rakoczy</surname><given-names>PE</given-names></name></person-group><article-title>Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA</article-title><source>Exp Eye Res</source><year>2002</year><volume>75</volume><fpage>625</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">12470964</pub-id>
</element-citation></ref><ref id="R112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qazi</surname><given-names>Y</given-names></name>
<name><surname>Stagg</surname><given-names>B</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Luo</surname><given-names>L</given-names></name>
<etal/></person-group><article-title>Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization</article-title><source>Invest Ophthalmol Vis Sci</source><year>2012</year><volume>53</volume><fpage>2837</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22467572</pub-id>
</element-citation></ref><ref id="R113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>HC</given-names></name>
<name><surname>Yeh</surname><given-names>SI</given-names></name>
<name><surname>Tsao</surname><given-names>YP</given-names></name>
<name><surname>Kuo</surname><given-names>PC</given-names></name></person-group><article-title>Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>2344</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">18199977</pub-id>
</element-citation></ref><ref id="R114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parker</surname><given-names>M</given-names></name>
<name><surname>Bellec</surname><given-names>J</given-names></name>
<name><surname>McFarland</surname><given-names>T</given-names></name>
<name><surname>Scripps</surname><given-names>V</given-names></name>
<name><surname>Appukuttan</surname><given-names>B</given-names></name>
<name><surname>Hartzell</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Suppression of neovascularization of donor corneas by transduction with equine infectious anemia virus-based lentiviral vectors expressing endostatin and angiostatin</article-title><source>Hum Gene Ther</source><year>2014</year><volume>25</volume><fpage>408</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">24460027</pub-id>
</element-citation></ref><ref id="R115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Torrecilla</surname><given-names>J</given-names></name>
<name><surname>G&#x000f3;mez-Aguado</surname><given-names>I</given-names></name>
<name><surname>Vicente-Pascual</surname><given-names>M</given-names></name>
<name><surname>Del Pozo-Rodr&#x000ed;guez</surname><given-names>A</given-names></name>
<name><surname>Solin&#x000ed;s</surname><given-names>M</given-names></name>
<name><surname>Rodr&#x000ed;guez- Gasc&#x000f3;n</surname><given-names>A</given-names></name></person-group><article-title>MMP-9 downregulation with lipid nanoparticles for inhibiting corneal neovascularization by gene silencing</article-title><source>Nanomaterials (Basel)</source><year>2019</year><volume>9</volume><fpage>631</fpage><pub-id pub-id-type="pmid">31003493</pub-id>
</element-citation></ref><ref id="R116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>F</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Hu</surname><given-names>Y</given-names></name>
<name><surname>Fu</surname><given-names>Y</given-names></name>
<etal/></person-group><article-title>Cholesterol modification of SDF-1-specific siRNA enables therapeutic targeting of angiogenesis through Akt pathway inhibition</article-title><source>Exp Eye Res</source><year>2019</year><volume>184</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">30898556</pub-id>
</element-citation></ref><ref id="R117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>Deng</surname><given-names>Z</given-names></name>
<name><surname>Zhong</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>Efficient ocular delivery of siRNA via pH-sensitive vehicles for corneal neovascularization inhibition</article-title><source>Int J Pharm X</source><year>2023</year><volume>5</volume><fpage>100183</fpage><pub-id pub-id-type="pmid">37234133</pub-id>
</element-citation></ref><ref id="R118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cursiefen</surname><given-names>C</given-names></name>
<name><surname>Viaud</surname><given-names>E</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Geudelin</surname><given-names>B</given-names></name>
<name><surname>Ferry</surname><given-names>A</given-names></name>
<name><surname>Kadlecov&#x000e1;</surname><given-names>P</given-names></name>
<etal/></person-group><article-title>Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: The I-CAN study</article-title><source>Ophthalmology</source><year>2014</year><volume>121</volume><fpage>1683</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">24811963</pub-id>
</element-citation></ref><ref id="R119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Yin</surname><given-names>Y</given-names></name>
<name><surname>Zhao</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<etal/></person-group><article-title>An update on novel ocular nanosystems with possible benefits in the treatment of corneal neovascularization</article-title><source>Int J Nanomedicine</source><year>2022</year><volume>17</volume><fpage>4911</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">36267540</pub-id>
</element-citation></ref><ref id="R120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hos</surname><given-names>D</given-names></name>
<name><surname>Saban</surname><given-names>DR</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Regenfuss</surname><given-names>B</given-names></name>
<name><surname>Onderka</surname><given-names>J</given-names></name>
<name><surname>Masli</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Suppression of Inflammatory corneal lymphangiogenesis by application of topical corticosteroids</article-title><source>Arch Ophthalmol</source><year>2011</year><volume>129</volume><fpage>445</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">21482870</pub-id>
</element-citation></ref><ref id="R121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cooper</surname><given-names>CA</given-names></name>
<name><surname>Bergamini</surname><given-names>MVW</given-names></name>
<name><surname>Leopold</surname><given-names>IH</given-names></name></person-group><article-title>Use of flurbiprofen to inhibit corneal neovascularization</article-title><source>Arch Ophthalmol</source><year>1980</year><volume>98</volume><fpage>1102</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">6155898</pub-id>
</element-citation></ref><ref id="R122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pakneshan</surname><given-names>P</given-names></name>
<name><surname>Birsner</surname><given-names>AE</given-names></name>
<name><surname>Adini</surname><given-names>I</given-names></name>
<name><surname>Becker</surname><given-names>CM</given-names></name>
<name><surname>D&#x02019;Amato</surname><given-names>RJ</given-names></name></person-group><article-title>Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs</article-title><source>Invest Ophthalmol Vis Sci</source><year>2008</year><volume>49</volume><fpage>3909</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">18487370</pub-id>
</element-citation></ref><ref id="R123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ulusoy</surname><given-names>DM</given-names></name>
<name><surname>Kahraman</surname><given-names>N</given-names></name>
<name><surname>Balc&#x00131;o&#x0011f;lu</surname><given-names>E</given-names></name>
<name><surname>Duru</surname><given-names>Z</given-names></name></person-group><article-title>Comparison of the inhibitory effect of topical cyclosporine A 0.1% and topical anti-VEGF application in an experimental model of corneal neovascularization</article-title><source>Arq Bras Oftalmol</source><year>2022</year><volume>85</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">34586225</pub-id>
</element-citation></ref><ref id="R124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Byun</surname><given-names>YS</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>The effect of methotrexate on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2011</year><volume>30</volume><fpage>442</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21389805</pub-id>
</element-citation></ref><ref id="R125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kruse</surname><given-names>FE</given-names></name>
<name><surname>Joussen</surname><given-names>AM</given-names></name>
<name><surname>Rohrschneider</surname><given-names>K</given-names></name>
<name><surname>Becker</surname><given-names>MD</given-names></name>
<name><surname>V&#x000f6;lcker</surname><given-names>HE</given-names></name></person-group><article-title>Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>1998</year><volume>236</volume><fpage>461</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9646092</pub-id>
</element-citation></ref><ref id="R126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abbas</surname><given-names>A</given-names></name>
<name><surname>Khan</surname><given-names>B</given-names></name>
<name><surname>Feroze</surname><given-names>AH</given-names></name>
<name><surname>Hyman</surname><given-names>GF</given-names></name></person-group><article-title>Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis</article-title><source>J Pak Med Assoc</source><year>2002</year><volume>52</volume><fpage>476</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12553678</pub-id>
</element-citation></ref><ref id="R127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>YK</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>The inhibitory effect of thalidomide analogue on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2013</year><volume>32</volume><fpage>1142</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23739149</pub-id>
</element-citation></ref><ref id="R128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dana</surname><given-names>MR</given-names></name>
<name><surname>Zhu</surname><given-names>SN</given-names></name>
<name><surname>Yamada</surname><given-names>J</given-names></name></person-group><article-title>Topical modulation of interleukin-1 activity in corneal neovascularization</article-title><source>Cornea</source><year>1998</year><volume>17</volume><fpage>403</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9676913</pub-id>
</element-citation></ref><ref id="R129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000d6;zkaya</surname><given-names>D</given-names></name>
<name><surname>Karaca</surname><given-names>U</given-names></name>
<name><surname>Usta Sofu</surname><given-names>G</given-names></name>
<name><surname>Savran</surname><given-names>M</given-names></name>
<name><surname>&#x000d6;zg&#x000f6;&#x000e7;men</surname><given-names>M</given-names></name>
<name><surname>Ertu&#x0011f;rul</surname><given-names>A</given-names></name></person-group><article-title>Effect of adalimumab on experimental corneal neovascularization model</article-title><source>Int Ophthalmol</source><year>2023</year><volume>43</volume><fpage>2119</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">37012439</pub-id>
</element-citation></ref><ref id="R130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amparo</surname><given-names>F</given-names></name>
<name><surname>Sadrai</surname><given-names>Z</given-names></name>
<name><surname>Jin</surname><given-names>Y</given-names></name>
<name><surname>Alfonso-Bartolozzi</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Shikari</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization</article-title><source>Invest Ophthalmol Vis Sci</source><year>2013</year><volume>54</volume><fpage>537</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">23233252</pub-id>
</element-citation></ref><ref id="R131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>JH</given-names></name>
<name><surname>Tseng</surname><given-names>CL</given-names></name>
<name><surname>Lin</surname><given-names>FL</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Hsieh</surname><given-names>EH</given-names></name>
<name><surname>Lama</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Topical application of TAK1 inhibitor encapsulated by gelatin particle alleviates corneal neovascularization</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>657</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">34976206</pub-id>
</element-citation></ref><ref id="R132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dastjerdi</surname><given-names>MH</given-names></name>
<name><surname>Saban</surname><given-names>DR</given-names></name>
<name><surname>Okanobo</surname><given-names>A</given-names></name>
<name><surname>Nallasamy</surname><given-names>N</given-names></name>
<name><surname>Sadrai</surname><given-names>Z</given-names></name>
<name><surname>Chauhan</surname><given-names>SK</given-names></name>
<etal/></person-group><article-title>Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><fpage>2411</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19892863</pub-id>
</element-citation></ref><ref id="R133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petsoglou</surname><given-names>C</given-names></name>
<name><surname>Balaggan</surname><given-names>KS</given-names></name>
<name><surname>Dart</surname><given-names>JK</given-names></name>
<name><surname>Bunce</surname><given-names>C</given-names></name>
<name><surname>Xing</surname><given-names>W</given-names></name>
<name><surname>Ali</surname><given-names>RR</given-names></name>
<etal/></person-group><article-title>Subconjunctival bevacizumab induces regression of corneal neovascularisation: A pilot randomised placebo-controlled double- masked trial</article-title><source>Br J Ophthalmol</source><year>2013</year><volume>97</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">23087419</pub-id>
</element-citation></ref><ref id="R134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>EK</given-names></name>
<name><surname>Kong</surname><given-names>SJ</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2014</year><volume>33</volume><fpage>60</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">24240485</pub-id>
</element-citation></ref><ref id="R135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>HB</given-names></name>
<name><surname>Sakimoto</surname><given-names>T</given-names></name>
<name><surname>Javier</surname><given-names>JA</given-names></name>
<name><surname>Azar</surname><given-names>DT</given-names></name>
<name><surname>Wiegand</surname><given-names>SJ</given-names></name>
<name><surname>Jain</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>VEGF Trap(R1R2) suppresses experimental corneal angiogenesis</article-title><source>Eur J Ophthalmol</source><year>2010</year><volume>20</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">19882518</pub-id>
</element-citation></ref><ref id="R136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eski</surname><given-names>M</given-names></name>
<name><surname>Teberik</surname><given-names>K</given-names></name>
<name><surname>Oltulu</surname><given-names>P</given-names></name>
<name><surname>Ankaral&#x00131;</surname><given-names>H</given-names></name>
<name><surname>Kaya</surname><given-names>M</given-names></name>
<name><surname>Alpay</surname><given-names>M</given-names></name></person-group><article-title>The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization</article-title><source>Hum Exp Toxicol</source><year>2022</year><volume>41</volume><fpage>09603271221084674</fpage></element-citation></ref><ref id="R137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>XR</given-names></name>
<name><surname>Xu</surname><given-names>HC</given-names></name>
<name><surname>Ma</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>LY</given-names></name>
<name><surname>Zhai</surname><given-names>LY</given-names></name>
<etal/></person-group><article-title>Effects of VEGF inhibitor conbercept on corneal neovascularization following penetrating keratoplasty in rabbit model</article-title><source>Clin Ophthalmol</source><year>2020</year><volume>14</volume><fpage>2185</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">32801629</pub-id>
</element-citation></ref><ref id="R138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>L</given-names></name>
<name><surname>Sun</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Xu</surname><given-names>N</given-names></name>
<name><surname>Liu</surname><given-names>M</given-names></name>
<name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>Effect of conbercept on corneal neovascularization in a rabbit model</article-title><source>Semin Ophthalmol</source><year>2023</year><volume>38</volume><fpage>670</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">37058000</pub-id>
</element-citation></ref><ref id="R139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>C</given-names></name>
<name><surname>Ruan</surname><given-names>F</given-names></name>
<name><surname>Li</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>JQ</given-names></name>
<name><surname>Jie</surname><given-names>Y</given-names></name></person-group><article-title>Subconjunctival conbercept for the treatment of corneal neovascularization</article-title><source>Int J Ophthalmol</source><year>2023</year><volume>16</volume><fpage>871</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">37332556</pub-id>
</element-citation></ref><ref id="R140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cherry</surname><given-names>PM</given-names></name>
<name><surname>Garner</surname><given-names>A</given-names></name></person-group><article-title>Corneal neovascularization treated with argon laser</article-title><source>Br J Ophthalmol</source><year>1976</year><volume>60</volume><fpage>464</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">986151</pub-id>
</element-citation></ref><ref id="R141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>YJ</given-names></name>
<name><surname>Mann</surname><given-names>RK</given-names></name>
<name><surname>Mah</surname><given-names>TS</given-names></name>
<name><surname>Gorin</surname><given-names>MB</given-names></name></person-group><article-title>Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization</article-title><source>Cornea</source><year>2002</year><volume>21</volume><fpage>770</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12410033</pub-id>
</element-citation></ref><ref id="R142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Primbs</surname><given-names>GB</given-names></name>
<name><surname>Casey</surname><given-names>R</given-names></name>
<name><surname>Wamser</surname><given-names>K</given-names></name>
<name><surname>Snyder</surname><given-names>WJ</given-names></name>
<name><surname>Crean</surname><given-names>DH</given-names></name></person-group><article-title>Photodynamic therapy for corneal neovascularization</article-title><source>Ophthalmic Surg Lasers</source><year>1998</year><volume>29</volume><fpage>832</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9793949</pub-id>
</element-citation></ref><ref id="R143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Al-Torbak</surname><given-names>AA</given-names></name></person-group><article-title>Photodynamic therapy with verteporfin for corneal neovascularization</article-title><source>Middle East Afr J Ophthalmol</source><year>2012</year><volume>19</volume><fpage>185</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22623856</pub-id>
</element-citation></ref><ref id="R144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>KC</given-names></name>
<name><surname>You</surname><given-names>IC</given-names></name>
<name><surname>Kang</surname><given-names>IS</given-names></name>
<name><surname>Im</surname><given-names>SK</given-names></name>
<name><surname>Ahn</surname><given-names>JK</given-names></name>
<name><surname>Park</surname><given-names>YG</given-names></name>
<etal/></person-group><article-title>Photodynamic therapy with verteporfin for corneal neovascularization</article-title><source>Am J Ophthalmol</source><year>2007</year><volume>144</volume><fpage>390</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17631268</pub-id>
</element-citation></ref><ref id="R145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Romano</surname><given-names>V</given-names></name>
<name><surname>Steger</surname><given-names>B</given-names></name>
<name><surname>Brunner</surname><given-names>M</given-names></name>
<name><surname>Ahmad</surname><given-names>S</given-names></name>
<name><surname>Willoughby</surname><given-names>CE</given-names></name>
<name><surname>Kaye</surname><given-names>SB</given-names></name></person-group><article-title>Method for angiographically guided fine-needle diathermy in the treatment of corneal neovascularization</article-title><source>Cornea</source><year>2016</year><volume>35</volume><fpage>1029</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">27149536</pub-id>
</element-citation></ref><ref id="R146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Mo</surname><given-names>K</given-names></name>
<name><surname>Guo</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>Cotransplantation of limbal epithelial and stromal cells for ocular surface reconstruction</article-title><source>Ophthalmol Sci</source><year>2022</year><volume>2</volume><fpage>100148</fpage><pub-id pub-id-type="pmid">36249679</pub-id>
</element-citation></ref><ref id="R147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zakaria</surname><given-names>N</given-names></name>
<name><surname>Possemiers</surname><given-names>T</given-names></name>
<name><surname>Dhubhghaill</surname><given-names>SN</given-names></name>
<name><surname>Leysen</surname><given-names>I</given-names></name>
<name><surname>Rozema</surname><given-names>J</given-names></name>
<name><surname>Koppen</surname><given-names>C</given-names></name>
<etal/></person-group><article-title>Results of a phase I/II clinical trial: Standardized, non-xenogenic, cultivated limbal stem cell transplantation</article-title><source>J Transl Med</source><year>2014</year><volume>12</volume><fpage>58</fpage><pub-id pub-id-type="pmid">24589151</pub-id>
</element-citation></ref><ref id="R148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>Q</given-names></name>
<name><surname>Chauhan</surname><given-names>T</given-names></name>
<name><surname>Yung</surname><given-names>M</given-names></name>
<name><surname>Tseng</surname><given-names>C-H</given-names></name>
<name><surname>Deng</surname><given-names>SX</given-names></name></person-group><article-title>Outcomes of limbal stem cell transplant: A meta-analysis</article-title><source>JAMA Ophthalmol</source><year>2020</year><volume>138</volume><fpage>660</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">32324211</pub-id>
</element-citation></ref><ref id="R149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>T</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Effect of collagen cross-linking on alkali burn-induced corneal neovascularization in rabbits</article-title><source>J Ophthalmol</source><year>2018</year><volume>2018</volume><fpage>7325483</fpage><pub-id pub-id-type="pmid">30402279</pub-id>
</element-citation></ref><ref id="R150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kesim</surname><given-names>E</given-names></name>
<name><surname>Pirhan</surname><given-names>D</given-names></name>
<name><surname>Yardimoglu Yilmaz</surname><given-names>M</given-names></name>
<name><surname>Yuksel</surname><given-names>N</given-names></name>
<name><surname>Yazir</surname><given-names>Y</given-names></name>
<name><surname>Bicaklioglu</surname><given-names>G</given-names></name>
<etal/></person-group><article-title>Comparative analysis of matrix-regenerating agent and corneal cross-linking in an experimental alkali burn rabbit model</article-title><source>Curr Eye Res</source><year>2022</year><volume>47</volume><fpage>187</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">34435926</pub-id>
</element-citation></ref><ref id="R151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lyu</surname><given-names>N</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Xiang</surname><given-names>J</given-names></name>
<name><surname>Fan</surname><given-names>X</given-names></name>
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Sun</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>Inhibiting corneal neovascularization by sustainably releasing anti-VEGF and anti-inflammation drugs from silica-thermogel nanohybrids</article-title><source>Mater Sci Eng C Mater Biol Appl</source><year>2021</year><volume>128</volume><fpage>112274</fpage><pub-id pub-id-type="pmid">34474833</pub-id>
</element-citation></ref><ref id="R152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Di Tommaso</surname><given-names>C</given-names></name>
<name><surname>Bourges</surname><given-names>JL</given-names></name>
<name><surname>Valamanesh</surname><given-names>F</given-names></name>
<name><surname>Trubitsyn</surname><given-names>G</given-names></name>
<name><surname>Torriglia</surname><given-names>A</given-names></name>
<name><surname>Jeanny</surname><given-names>JC</given-names></name>
<etal/></person-group><article-title>Novel micelle carriers for cyclosporin A topical ocular delivery: In vivo cornea penetration, ocular distribution and efficacy studies</article-title><source>Eur J Pharm Biopharm</source><year>2012</year><volume>81</volume><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">22445900</pub-id>
</element-citation></ref><ref id="R153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chuang</surname><given-names>YL</given-names></name>
<name><surname>Fang</surname><given-names>HW</given-names></name>
<name><surname>Ajitsaria</surname><given-names>A</given-names></name>
<name><surname>Chen</surname><given-names>KH</given-names></name>
<name><surname>Su</surname><given-names>CY</given-names></name>
<name><surname>Liu</surname><given-names>GS</given-names></name>
<etal/></person-group><article-title>Development of Kaempferol- loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><fpage>635</fpage><pub-id pub-id-type="pmid">31795237</pub-id>
</element-citation></ref><ref id="R154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>YC</given-names></name>
<name><surname>Fang</surname><given-names>HW</given-names></name>
<name><surname>Wu</surname><given-names>YY</given-names></name>
<name><surname>Tang</surname><given-names>YJ</given-names></name>
<name><surname>Hsieh</surname><given-names>EH</given-names></name>
<name><surname>She</surname><given-names>Y</given-names></name>
<etal/></person-group><article-title>Functional peptide-loaded gelatin nanoparticles as eyedrops for cornea neovascularization treatment</article-title><source>Int J Nanomedicine</source><year>2023</year><volume>18</volume><fpage>1413</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">36992821</pub-id>
</element-citation></ref><ref id="R155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X-P</given-names></name>
<name><surname>Sun</surname><given-names>J-G</given-names></name>
<name><surname>Yao</surname><given-names>J</given-names></name>
<name><surname>Shan</surname><given-names>K</given-names></name>
<name><surname>Liu</surname><given-names>B-H</given-names></name>
<name><surname>Yao</surname><given-names>M-D</given-names></name>
<etal/></person-group><article-title>Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>107</volume><fpage>1056</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">30257317</pub-id>
</element-citation></ref><ref id="R156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>WK</given-names></name>
<name><surname>Kang</surname><given-names>S</given-names></name>
<name><surname>Choi</surname><given-names>H</given-names></name>
<name><surname>Rho</surname><given-names>CR</given-names></name></person-group><article-title>Topically administered gold nanoparticles inhibit experimental corneal neovascularization in mice</article-title><source>Cornea</source><year>2015</year><volume>34</volume><fpage>456</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">25625363</pub-id>
</element-citation></ref><ref id="R157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>Q</given-names></name>
<name><surname>Fang</surname><given-names>Y</given-names></name>
<name><surname>Zeng</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>Song</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>Cytocompatible cerium oxide-mediated antioxidative stress in inhibiting ocular inflammation-associated corneal neovascularization</article-title><source>J Mater Chem B</source><year>2019</year><volume>7</volume><fpage>6759</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">31593203</pub-id>
</element-citation></ref><ref id="R158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Delgado-Tirado</surname><given-names>S</given-names></name>
<name><surname>Gonzalez-Buendia</surname><given-names>L</given-names></name>
<name><surname>An</surname><given-names>M</given-names></name>
<name><surname>Amarnani</surname><given-names>D</given-names></name>
<name><surname>Isaacs-Bernal</surname><given-names>D</given-names></name>
<name><surname>Whitmore</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>Topical nanoemulsion of a runt-related transcription factor 1 inhibitor for the treatment of pathologic ocular angiogenesis</article-title><source>Ophthalmol Sci</source><year>2022</year><volume>2</volume><fpage>100163</fpage><pub-id pub-id-type="pmid">36213726</pub-id>
</element-citation></ref><ref id="R159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soiberman</surname><given-names>U</given-names></name>
<name><surname>Kambhampati</surname><given-names>SP</given-names></name>
<name><surname>Wu</surname><given-names>T</given-names></name>
<name><surname>Mishra</surname><given-names>MK</given-names></name>
<name><surname>Oh</surname><given-names>Y</given-names></name>
<name><surname>Sharma</surname><given-names>R</given-names></name>
<etal/></person-group><article-title>Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation</article-title><source>Biomaterials</source><year>2017</year><volume>125</volume><fpage>38</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">28226245</pub-id>
</element-citation></ref><ref id="R160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>X</given-names></name>
<name><surname>Marcano</surname><given-names>DC</given-names></name>
<name><surname>Shin</surname><given-names>CS</given-names></name>
<name><surname>Hua</surname><given-names>X</given-names></name>
<name><surname>Isenhart</surname><given-names>LC</given-names></name>
<name><surname>Pflugfelder</surname><given-names>SC</given-names></name>
<etal/></person-group><article-title>Ocular drug delivery nanowafer with enhanced therapeutic efficacy</article-title><source>ACS Nano</source><year>2015</year><volume>9</volume><fpage>1749</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">25585134</pub-id>
</element-citation></ref><ref id="R161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikolic</surname><given-names>L</given-names></name>
<name><surname>Friend</surname><given-names>J</given-names></name>
<name><surname>Taylor</surname><given-names>S</given-names></name>
<name><surname>Thoft</surname><given-names>R</given-names></name></person-group><article-title>Inhibition of vascularization in rabbit corneas by heparin: Cortisone pellets</article-title><source>Invest Ophthalmol Vis Sci</source><year>1986</year><volume>27</volume><fpage>449</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">2420742</pub-id>
</element-citation></ref><ref id="R162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aydin</surname><given-names>E</given-names></name>
<name><surname>Kivilcim</surname><given-names>M</given-names></name>
<name><surname>Peyman</surname><given-names>GA</given-names></name>
<name><surname>Esfahani</surname><given-names>MR</given-names></name>
<name><surname>Kazi</surname><given-names>AA</given-names></name>
<name><surname>Sanders</surname><given-names>DR</given-names></name></person-group><article-title>Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline</article-title><source>Cornea</source><year>2008</year><volume>27</volume><fpage>446</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18434849</pub-id>
</element-citation></ref><ref id="R163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tommila</surname><given-names>P</given-names></name>
<name><surname>Summanen</surname><given-names>P</given-names></name>
<name><surname>Tervo</surname><given-names>T</given-names></name></person-group><article-title>Cortisone, heparin and argon laser in the treatment of corneal neovascularization</article-title><source>Acta Ophthalmol Suppl (1985)</source><year>1987</year><volume>182</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">2454014</pub-id>
</element-citation></ref><ref id="R164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>S</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2010</year><volume>29</volume><fpage>192</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20098156</pub-id>
</element-citation></ref><ref id="R165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>H</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<name><surname>Xing</surname><given-names>C</given-names></name>
<name><surname>Li</surname><given-names>S</given-names></name>
<name><surname>Bao</surname><given-names>Z</given-names></name>
<name><surname>Lei</surname><given-names>L</given-names></name>
<etal/></person-group><article-title>An injectable thermosensitive hydrogel for dual delivery of diclofenac and Avastin&#x000ae; to effectively suppress inflammatory corneal neovascularization</article-title><source>Int J Pharm</source><year>2022</year><volume>625</volume><fpage>122081</fpage><pub-id pub-id-type="pmid">35934166</pub-id>
</element-citation></ref><ref id="R166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>C</given-names></name>
<name><surname>Lei</surname><given-names>F</given-names></name>
<name><surname>Sharma</surname><given-names>J</given-names></name>
<name><surname>Hui</surname><given-names>PC</given-names></name>
<name><surname>Wolkow</surname><given-names>N</given-names></name>
<name><surname>Dohlman</surname><given-names>CH</given-names></name>
<etal/></person-group><article-title>Sustained Inhibition of VEGF and TNF-&#x003b1; achieves multi-ocular protection and prevents formation of blood vessels after severe ocular trauma</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><fpage>2059</fpage><pub-id pub-id-type="pmid">37631272</pub-id>
</element-citation></ref><ref id="R167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerten</surname><given-names>G</given-names></name></person-group><article-title>Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery</article-title><source>Cornea</source><year>2008</year><volume>27</volume><fpage>1195</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19034142</pub-id>
</element-citation></ref><ref id="R168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anand</surname><given-names>N</given-names></name>
<name><surname>Reidy</surname><given-names>JJ</given-names></name>
<name><surname>Riaz</surname><given-names>KM</given-names></name></person-group><article-title>Short-term regression of corneal neovascularization with combination therapy of argon green laser photocoagulation and subconjunctival bevacizumab</article-title><source>Int Med Case Rep J</source><year>2019</year><volume>12</volume><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">31114395</pub-id>
</element-citation></ref><ref id="R169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Donato</surname><given-names>MG</given-names></name>
<name><surname>Donato</surname><given-names>E</given-names></name>
<name><surname>Cordeiro M&#x000c1;</surname><given-names>C</given-names></name>
<name><surname>Martins de Andrade</surname><given-names>M</given-names></name>
<name><surname>Holanda de Freitas</surname><given-names>JA</given-names></name></person-group><article-title>Treating corneal neovascularization using a combination of anti-VEGF injection and argon laser photocoagulation application - case report</article-title><source>Rom J Ophthalmol</source><year>2021</year><volume>65</volume><fpage>286</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">35036654</pub-id>
</element-citation></ref><ref id="R170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>RY</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name>
<name><surname>Kim</surname><given-names>MS</given-names></name>
<name><surname>Ra</surname><given-names>H</given-names></name></person-group><article-title>Effects of combined photodynamic therapy and topical bevacizumab treatment on corneal neovascularization in rabbits</article-title><source>Cornea</source><year>2016</year><volume>35</volume><fpage>1615</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">27684458</pub-id>
</element-citation></ref><ref id="R171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamdan</surname><given-names>J</given-names></name>
<name><surname>Boulze</surname><given-names>M</given-names></name>
<name><surname>Aziz</surname><given-names>A</given-names></name>
<name><surname>Alessi</surname><given-names>G</given-names></name>
<name><surname>Hoffart</surname><given-names>L</given-names></name></person-group><article-title>[Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy]</article-title><source>J Fr Ophtalmol</source><year>2015</year><volume>38</volume><fpage>924</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">26522892</pub-id>
</element-citation></ref><ref id="R172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>HJ</given-names></name>
<name><surname>Kim</surname><given-names>MK</given-names></name>
<name><surname>Seo</surname><given-names>KY</given-names></name>
<name><surname>Ueta</surname><given-names>M</given-names></name>
<name><surname>Yoon</surname><given-names>KC</given-names></name></person-group><article-title>Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens- Johnson syndrome</article-title><source>Int Ophthalmol</source><year>2019</year><volume>39</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">29256167</pub-id>
</element-citation></ref><ref id="R173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koenig</surname><given-names>Y</given-names></name>
<name><surname>Bock</surname><given-names>F</given-names></name>
<name><surname>Kruse</surname><given-names>FE</given-names></name>
<name><surname>Stock</surname><given-names>K</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name></person-group><article-title>Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: Fine-needle vessel coagulation combined with anti-VEGFs</article-title><source>Cornea</source><year>2012</year><volume>31</volume><fpage>887</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22362005</pub-id>
</element-citation></ref><ref id="R174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mestanoglu</surname><given-names>M</given-names></name>
<name><surname>H&#x000e4;ndel</surname><given-names>A</given-names></name>
<name><surname>Cursiefen</surname><given-names>C</given-names></name>
<name><surname>Hos</surname><given-names>D</given-names></name></person-group><article-title>Three-year follow-up of high-risk keratoplasty following fine-needle diathermy of corneal neovascularization combined with bevacizumab</article-title><source>Graefes Arch Clin Exp Ophthalmol</source><year>2022</year><volume>260</volume><fpage>2383</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">34989865</pub-id>
</element-citation></ref><ref id="R175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayashi</surname><given-names>T</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
<name><surname>Hos</surname><given-names>D</given-names></name>
<name><surname>Schrittenlocher</surname><given-names>S</given-names></name>
<name><surname>Nhat Hung Le</surname><given-names>V</given-names></name>
<name><surname>Siebelmann</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Descemet membrane endothelial keratoplasty in vascularized eyes: Outcome and effect on corneal neovascularization</article-title><source>Cornea</source><year>2021</year><volume>40</volume><fpage>685</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">33252385</pub-id>
</element-citation></ref><ref id="R176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>ZR</given-names></name>
<name><surname>Su</surname><given-names>WR</given-names></name>
<name><surname>Li</surname><given-names>YP</given-names></name>
<name><surname>Lin</surname><given-names>ML</given-names></name>
<name><surname>Zhang</surname><given-names>WX</given-names></name>
<etal/></person-group><article-title>Role of mesenchymal stem cells on cornea wound healing induced by acute alkali burn</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e30842</fpage><comment>doi: 10.1371/journal.pone.0030842</comment><pub-id pub-id-type="pmid">22363499</pub-id>
</element-citation></ref><ref id="R177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>HB</given-names></name>
<name><surname>Park</surname><given-names>SY</given-names></name>
<name><surname>Ko</surname><given-names>JH</given-names></name>
<name><surname>Park</surname><given-names>JW</given-names></name>
<name><surname>Yoon</surname><given-names>CH</given-names></name>
<name><surname>Kim</surname><given-names>DH</given-names></name>
<etal/></person-group><article-title>Mesenchymal stromal cells inhibit Inflammatory lymphangiogenesis in the cornea by suppressing macrophage in a TSG-6-dependent manner</article-title><source>Mol Ther</source><year>2018</year><volume>26</volume><fpage>162</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">29301108</pub-id>
</element-citation></ref><ref id="R178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>O</given-names></name>
<name><surname>Xie</surname><given-names>ZL</given-names></name>
<name><surname>Lin</surname><given-names>BW</given-names></name>
<name><surname>Yin</surname><given-names>XF</given-names></name>
<name><surname>Pi</surname><given-names>RB</given-names></name>
<name><surname>Zhou</surname><given-names>SY</given-names></name></person-group><article-title>Minocycline inhibits alkali burn-induced corneal neovascularization in mice</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e41858</fpage><pub-id pub-id-type="pmid">22848638</pub-id>
</element-citation></ref><ref id="R179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>YY</given-names></name>
<name><surname>Zhang</surname><given-names>HF</given-names></name>
<name><surname>Zhong</surname><given-names>JX</given-names></name>
<name><surname>Bai</surname><given-names>L</given-names></name>
<name><surname>Lu</surname><given-names>XH</given-names></name></person-group><article-title>Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK1/2 and p38 pathways</article-title><source>Int J Ophthalmol</source><year>2011</year><volume>4</volume><fpage>150</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">22553631</pub-id>
</element-citation></ref><ref id="R180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goktas</surname><given-names>S</given-names></name>
<name><surname>Erdogan</surname><given-names>E</given-names></name>
<name><surname>Sakarya</surname><given-names>R</given-names></name>
<name><surname>Sakarya</surname><given-names>Y</given-names></name>
<name><surname>Y&#x00131;lmaz</surname><given-names>M</given-names></name>
<name><surname>Ozcimen</surname><given-names>M</given-names></name>
<etal/></person-group><article-title>Inhibition of corneal neovascularization by topical and subconjunctival tigecycline</article-title><source>J Ophthalmol</source><year>2014</year><volume>2014</volume><fpage>452685</fpage><pub-id pub-id-type="pmid">25197558</pub-id>
</element-citation></ref><ref id="R181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Ye</surname><given-names>B</given-names></name>
<name><surname>Zhu</surname><given-names>L</given-names></name>
<name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>Epigallocatechin gallate inhibits corneal neovascularization in ratalkaline burn model</article-title><source>Pak J Pharm Sci</source><year>2018</year><volume>31</volume><issue>3(Supplementary)</issue><fpage>1087</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">29731448</pub-id>
</element-citation></ref><ref id="R182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bian</surname><given-names>F</given-names></name>
<name><surname>Zhang</surname><given-names>M-C</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name></person-group><article-title>Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo</article-title><source>Ophthalmologica</source><year>2008</year><volume>222</volume><fpage>178</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">18497527</pub-id>
</element-citation></ref><ref id="R183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JS</given-names></name>
<name><surname>Choi</surname><given-names>JS</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>The effect of curcumin on corneal neovascularization in rabbit eyes</article-title><source>Curr Eye Res</source><year>2010</year><volume>35</volume><fpage>274</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">20373893</pub-id>
</element-citation></ref><ref id="R184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>T</given-names></name>
<name><surname>Sano</surname><given-names>Y</given-names></name>
<name><surname>Kinoshita</surname><given-names>S</given-names></name></person-group><article-title>Effects of 1alpha,25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>154</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10634615</pub-id>
</element-citation></ref><ref id="R185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>MY</given-names></name>
<name><surname>Chung</surname><given-names>SK</given-names></name></person-group><article-title>Treatment of corneal neovascularization by topical application of ascorbic acid in the rabbit model</article-title><source>Cornea</source><year>2012</year><volume>31</volume><fpage>1165</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22832865</pub-id>
</element-citation></ref></ref-list></back></article>